Evidencia científica

Respaldado por estudios clínicos independientes

Basado en décadas de investigación científica y en más de 10 millones de dólares invertidos hasta la fecha en ensayos clínicos, Nurosym lidera una nueva categoría de tecnología que utiliza señales bioeléctricas para actuar sobre circuitos neuronales, mejorando funciones corporales esenciales sin intervención química ni quirúrgica. Nuestra misión: mejorar la calidad de vida de 1.000 millones de personas.

Basado en décadas de investigación científica y en más de 10 millones de dólares invertidos hasta la fecha en ensayos clínicos, Nurosym lidera una nueva categoría de tecnología que utiliza señales bioeléctricas para actuar sobre circuitos neuronales, mejorando funciones corporales esenciales sin intervención química ni quirúrgica. Nuestra misión: mejorar la calidad de vida de 1.000 millones de personas.

60+

Completed scientific studies

$10M+

Invested in trials

10+

Years in development

150+

Leading institutions

Clinical studies across 6 symptom areas

Choose an area to explore the strongest outcomes and supporting research.

Study areas

Disclaimers

*Featured papers represent a selection of our research. Some studies cannot be displayed in full due to publisher licensing and paywall restrictions. Contact our team for help accessing the complete research catalogue.

* Results are from peer-reviewed studies in specific study populations. Percentages reflect relative change compared with a placebo or control group, or with baseline, depending on the study design. Individual results may vary.

Anxiety & stress

Independent research has reported reductions in anxiety and depression following AVNT™.

Key results

Reduction in anxious states

35%

Reduction in anxious states

The Burns Anxiety Inventory measures the severity of anxiety across anxious thoughts, emotions and physical symptoms. Nurosym significantly reduced anxiety after 10 days, with improvements maintained at the one-month follow-up (p < 0.001). Vagus nerve stimulation supports these effects by increasing vagal tone.

1/3

improvement in Depressive States & Improved Mood

45%

improvement in Depressive States & Improved Mood

The Beck Depression Inventory measures the severity of depressive symptoms across mood, motivation and physical functioning. AVNT™ reduced scores by approximately 45% after 10 days, with improvements appearing within five days (p<0.05).

2/3

reduction in blood pressure

10%

reduction in blood pressure

Systolic blood pressure measures pressure as the heart contracts, while diastolic pressure measures it between beats. Over three months, Nurosym reduced systolic pressure by 9.7% and diastolic pressure by 10.2% in young adults with Grade 1 hypertension.

3/3

Research papers (6)

Published 2025

Active tVNS reduced anxiety symptoms

In a randomized community study, active stimulation outperformed sham for reducing anxiety symptoms during the early treatment phase. The findings support tVNS as a promising tool for emotional regulation.

Study details
Jackowska et al. • 70 participants
Research institution
SWPS University; University of Ostrava
Published 2025

tVNS enhanced self-compassion training

In a preregistered randomized trial, combining tVNS with self-compassion imagery produced a larger immediate increase in self-compassion. The combination also supported rapid improvements in mindfulness.

Study details
Kamboj et al. • 120 participants
Research institution
University College London
Published January 2026

tVNS shifted brain activity towards calm attentiveness

In healthy young adults, tVNS increased the alpha-to-theta brainwave ratio, a pattern associated with calm attentiveness. The change appeared with tVNS alone, demonstrating a distinct effect on neural activity.

Study details
Molaeizadeh et al. • 20 participants
Research institution
University of the Basque Country (UPV/EHU)
Published September 2026

taVNS shifts an EEG marker relevant to emotion regulation

In this randomized pilot, eight taVNS sessions produced a significantly greater change in the Alpha/Theta EEG ratio than waitlist control, with increases in all five stimulated participants. All 40 sessions were completed and no serious adverse events occurred.

Study details
Molaeizadeh et al. • 10 participants (5 taVNS, 5 waitlist control)
Research institution
University of the Basque Country; Warsaw University of Technology; Jundi-Shapur University of Technology
Published 2021

tVNS eased fatigue, low mood and digestive symptoms in Long COVID

Following 10 daily sessions, participants reported 48% less fatigue and 45% fewer depressive symptoms. Gastrointestinal symptoms improved by 80%, with additional improvements in pain and cognitive difficulties.

Study details
Verbanck et al. • 20 participants
Research institution
Université Libre de Bruxelles
Published May 2024

Ten days of tVNS improved multiple Long COVID symptoms

Women with Long COVID showed improvements in anxiety, cognition, sleep and mood following a 10-day at-home intervention. Anxiety fell by 35%, attention improved by 11%, and several benefits continued through one-month follow-up.

Study details
Zheng et al. • 24 participants
Research institution
Casa Colina Hospital and Centers for Healthcare; Institute of Advanced Consciousness Studies

Fatigue, energy & sleep

Independent studies in people with fibromyalgia and Long COVID reported improvements in sleep quality following AVNT™. Sleep was assessed using validated measures including the Pittsburgh Sleep Quality Index, which considers sleep duration, disturbances, time taken to fall asleep and daytime functioning.

Early research in people experiencing persistent fatigue following COVID-19 also reported reductions in fatigue following AVNT™.

Key results

reduced fatigue & increased energy

48%

reduced fatigue & increased energy

The Pichot Fatigue Scale measures fatigue through symptoms such as low energy, exhaustion and increased effort during everyday activities. Nurosym reduced fatigue scores by approximately 48% after 10 days (p<0.0001), with improvements sustained one week after therapy ended.

1/3

improved Brain Fog, Gastrointestinal Function & Pain (Post-viral Fatigue Symptoms)

61%

improved Brain Fog, Gastrointestinal Function & Pain (Post-viral Fatigue Symptoms)

Systolic blood pressure measures pressure as the heart contracts, while diastolic pressure measures it between beats. Over three months, Nurosym reduced systolic pressure by 9.7% and diastolic pressure by 10.2% in young adults with Grade 1 hypertension.

2/3

improvement in sleep scores

30%

improvement in sleep scores

The PSQI Sleep Disturbance Score measures how frequently problems interrupt or impair sleep. Nurosym significantly improved sleep disturbance scores over four weeks, with improvements appearing after two weeks (p<0.05).

3/3

Research papers (5)

Published 2025

AVNT™ improved sleep and reduced widespread pain in fibromyalgia

After four weeks of AVNT™, participants reported 30% better sleep quality and 38% less widespread pain. The study also found a meaningful reduction in the overall impact of fibromyalgia on daily life.

Study details
Dolcini et al. • 18 participants
Research institution
Sapienza University of Rome; AOU Policlinico Umberto I
Published 2026

Brief tVNS helped preserve vigilance during sleep deprivation

During 24 hours of military training without sleep, higher-intensity stimulation helped limit early-morning slowing when fatigue was at its peak. The strongest effects appeared in sustained-attention tasks that depend on remaining alert.

Study details
Passi et al. • 48 participants
Research institution
Finnish Institute of Occupational Health
Published 2021

tVNS eased fatigue, low mood and digestive symptoms in Long COVID

Following 10 daily sessions, participants reported 48% less fatigue and 45% fewer depressive symptoms. Gastrointestinal symptoms improved by 80%, with additional improvements in pain and cognitive difficulties.

Study details
Verbanck et al. • 20 participants
Research institution
Université Libre de Bruxelles
Published March 2023

Most participants with Long COVID responded positively

In an open-label study involving people with Long COVID and chronic-fatigue symptoms, a majority met the study’s threshold for a positive response. The findings supported advancing tVNS into larger controlled trials.

Study details
Natelson et al. • 17 enrolled; 15 evaluable
Research institution
Icahn School of Medicine at Mount Sinai
Published May 2024

Ten days of tVNS improved multiple Long COVID symptoms

Women with Long COVID showed improvements in anxiety, cognition, sleep and mood following a 10-day at-home intervention. Anxiety fell by 35%, attention improved by 11%, and several benefits continued through one-month follow-up.

Study details
Zheng et al. • 24 participants
Research institution
Casa Colina Hospital and Centers for Healthcare; Institute of Advanced Consciousness Studies

Focus, memory & cognition

Studies have reported improvements in memory, attention and reading, alongside reductions in brain fog.

Key results

improvement in Attention Deficiency Symptoms

11%

improvement in Attention Deficiency Symptoms

The Flanker task measures attention and inhibitory control—the ability to stay focused while filtering out distractions. Nurosym significantly improved scores after therapy (p<0.01), with improvements maintained at the one-month follow-up (p<0.001).

1/3

improvement in Memory Recall

mejora

improvement in Memory Recall

Learning-task test questions measure how accurately participants retain and recall newly learned information. Nurosym improved overall test performance compared with placebo, with the clearest benefit observed on memory-specific questions.

2/3

improvement in Reading and Learning

mejora

improvement in Reading and Learning

The Automaticity and Decoding tasks measure the speed and accuracy with which learned information is applied. When paired with training, Nurosym significantly improved both performance speed and accuracy compared with placebo (p<0.05).

3/3

Research papers (6)

Published 2021

tVNS eased fatigue, low mood and digestive symptoms in Long COVID

Following 10 daily sessions, participants reported 48% less fatigue and 45% fewer depressive symptoms. Gastrointestinal symptoms improved by 80%, with additional improvements in pain and cognitive difficulties.

Study details
Verbanck et al. • 20 participants
Research institution
Université Libre de Bruxelles
Published 2024

Two weeks of tVNS improved immediate recall

In a randomized trial, active tVNS improved immediate recall and short-term memory, outperforming sham across both treatment phases. Improvements in immediate recall remained visible at follow-up in the early-treatment group.

Study details
Cibulcova et al. • 76 participants
Research institution
University of Ostrava
Published 2025

tVNS enhanced self-compassion training

In a preregistered randomized trial, combining tVNS with self-compassion imagery produced a larger immediate increase in self-compassion. The combination also supported rapid improvements in mindfulness.

Study details
Kamboj et al. • 120 participants
Research institution
University College London
Published March 2023

Most participants with Long COVID responded positively

In an open-label study involving people with Long COVID and chronic-fatigue symptoms, a majority met the study’s threshold for a positive response. The findings supported advancing tVNS into larger controlled trials.

Study details
Natelson et al. • 17 enrolled; 15 evaluable
Research institution
Icahn School of Medicine at Mount Sinai
Published 2026

Brief tVNS helped preserve vigilance during sleep deprivation

During 24 hours of military training without sleep, higher-intensity stimulation helped limit early-morning slowing when fatigue was at its peak. The strongest effects appeared in sustained-attention tasks that depend on remaining alert.

Study details
Passi et al. • 48 participants
Research institution
Finnish Institute of Occupational Health
Published May 2024

Ten days of tVNS improved multiple Long COVID symptoms

Women with Long COVID showed improvements in anxiety, cognition, sleep and mood following a 10-day at-home intervention. Anxiety fell by 35%, attention improved by 11%, and several benefits continued through one-month follow-up.

Study details
Zheng et al. • 24 participants
Research institution
Casa Colina Hospital and Centers for Healthcare; Institute of Advanced Consciousness Studies

Gut health

Early research in people with Long COVID reported improvements in digestive function following AVNT™, measured as a secondary study outcome.

Key results

reduction in digestive issues

80%

reduction in digestive issues

This measure tracks how frequently participants reported gastrointestinal issues. Following Nurosym therapy, the frequency of reported GI issues decreased by 80% (p<0.001).

Research papers (2)

Published 2021

tVNS eased fatigue, low mood and digestive symptoms in Long COVID

Following 10 daily sessions, participants reported 48% less fatigue and 45% fewer depressive symptoms. Gastrointestinal symptoms improved by 80%, with additional improvements in pain and cognitive difficulties.

Study details
Verbanck et al. • 20 participants
Research institution
Université Libre de Bruxelles
Published February 2024

Daily tVNS reduced excessive heart-rate rise in POTS

In a randomized, sham-controlled trial, two months of daily stimulation reduced postural heart-rate abnormalities by 45%. The active group also showed better HRV and lower inflammatory activity.

Study details
Stavrakis et al. • 26 participants
Research institution
University of Oklahoma Health Sciences Center

Pain & inflammation

In fibromyalgia studies, AVNT™ was associated with reductions in widespread pain and measures related to central sensitisation, the nervous system’s increased sensitivity to pain. Separate research in heart failure populations reported reductions in inflammatory and oxidative stress markers.

Key results

reduction in inflammatory markers

78%

reduction in inflammatory markers

IL-6 is an inflammatory cytokine used as a marker of inflammation in the body. After three months, IL-6 decreased by 78% with Nurosym, compared with 8% in the placebo group (p=0.013).

1/2

reduction in widespread pain index

38%

reduction in widespread pain index

The Widespread Pain Index (WPI) is a core component of the American College of Rheumatology’s diagnostic criteria for fibromyalgia. It counts the number of body regions — out of 19 standard areas — where a patient has experienced pain over the past week, giving a validated measure of how widely pain is distributed through the body. In a published pilot study using Parasym's device in fibromyalgia patients, WPI dropped significantly after four weeks of treatment, falling 37.8% from baseline (p=0.004).

2/2

Research papers (4)

Published 2021

tVNS eased fatigue, low mood and digestive symptoms in Long COVID

Following 10 daily sessions, participants reported 48% less fatigue and 45% fewer depressive symptoms. Gastrointestinal symptoms improved by 80%, with additional improvements in pain and cognitive difficulties.

Study details
Verbanck et al. • 20 participants
Research institution
Université Libre de Bruxelles
Published 2025

AVNT™ improved sleep and reduced widespread pain in fibromyalgia

After four weeks of AVNT™, participants reported 30% better sleep quality and 38% less widespread pain. The study also found a meaningful reduction in the overall impact of fibromyalgia on daily life.

Study details
Dolcini et al. • 18 participants
Research institution
Sapienza University of Rome; AOU Policlinico Umberto I
Published March 2023

Most participants with Long COVID responded positively

In an open-label study involving people with Long COVID and chronic-fatigue symptoms, a majority met the study’s threshold for a positive response. The findings supported advancing tVNS into larger controlled trials.

Study details
Natelson et al. • 17 enrolled; 15 evaluable
Research institution
Icahn School of Medicine at Mount Sinai
Published March 2020

Six months of tVNS dramatically reduced atrial fibrillation burden

In a double-blind, sham-controlled trial, daily stimulation reduced atrial fibrillation burden by 85%. It also lowered TNF-alpha, an inflammatory marker, by 23%.

Study details
Stavrakis et al. • 53 participants
Research institution
University of Oklahoma Health Sciences Center

HRV & performance

Independent research has shown improvements in vagus nerve activity and HRV, supporting the body’s shift from fight or flight towards rest and recovery.

Key results

improved Heart Rate Variability

18%

improved Heart Rate Variability

RMSSD measures HRV (heart rate variability) and is the best indicator we have for nervous system resilience. A high level indicates your body’s psychophysiological self-repair mechanism is operating at its peak, and the brain is in sync with your heart, lungs, gut, and every other major organ.

1/4

vagal tone increase in 5 min

61%

vagal tone increase in 5 min

High-frequency (HF) power measures parasympathetic activity and serves as a marker of vagal tone. Nurosym increased HF power by 61% within five minutes (p=0.001).

2/4

reduction in Oxidative Stress (Reactive Oxygen Species)

28%

reduction in Oxidative Stress (Reactive Oxygen Species)

DCF fluorescence measures reactive oxygen species (ROS), with lower values indicating reduced cellular oxidative stress. Nurosym significantly reduced ROS levels (p=0.004), while placebo stimulation produced no significant change (p=0.10).

3/4

improvement on Cardio-Vagal Baroreflex Gain

34%

improvement on Cardio-Vagal Baroreflex Gain

Cardio-vagal baroreflex gain measures how effectively heart rate adjusts to changes in blood pressure, indicating autonomic cardiovascular function. A single Nurosym session significantly increased baroreflex gain in patients with chronic heart failure.

4/4

Research papers (4)

Published November 2022

tVNS increased vagus nerve activity and HRV within minutes

Morning stimulation increased vagus nerve activity by 61%, while HRV improved by 18%. Favourable autonomic effects emerged within the first 10 minutes of stimulation.

Study details
Geng et al. • 40 participants across two studies (24 + 16)
Research institution
Hebei University of Technology
Published 2025

Right-sided tVNS improved cardiovascular reflex control

A brief session improved cardio-vagal baroreflex gain in people with chronic heart failure. This reflex helps the heart respond to changes in blood pressure and is an important measure of cardiovascular control.

Study details
Gentile et al. • 16 participants
Research institution
Scuola Superiore Sant’Anna; Fondazione Toscana Gabriele Monasterio
Published February 2024

Daily tVNS reduced excessive heart-rate rise in POTS

In a randomized, sham-controlled trial, two months of daily stimulation reduced postural heart-rate abnormalities by 45%. The active group also showed better HRV and lower inflammatory activity.

Study details
Stavrakis et al. • 26 participants
Research institution
University of Oklahoma Health Sciences Center
Published August 2025

tVNS reduced frequent premature heartbeats

In a randomized crossover trial, active stimulation reduced the burden of premature ventricular contractions compared with sham. The effect was observed across different origins of the abnormal heartbeats.

Study details
Zafeiropoulos et al. • 36 randomized; 35 analysed
Research institution
Lenox Hill Hospital, Northwell Health; University of Oklahoma Health Sciences Center

Cardiovascular system

Across studies in different cardiovascular populations, AVNT™ was associated with improvements in heart rhythm, blood pressure, heart muscle function and blood flow through large and small blood vessels.

Key results

reduction in postural heart rate abnormalities

40%

reduction in postural heart rate abnormalities

Orthostatic heart-rate change measures how much the heart rate rises upon standing. After two months, the increase was 15 beats per minute lower with Nurosym than with placebo.

1/5

reduction in Atrial Fibrillation Burden

85%

reduction in Atrial Fibrillation Burden

Atrial fibrillation burden measures the proportion of monitored time spent experiencing an irregular heart rhythm. After six months, baseline-adjusted AF burden was lower with Nurosym than with placebo stimulation.

2/5

improvement of Heart Muscle Function (Global Longitude Strain reduction)

19%

improvement of Heart Muscle Function (Global Longitude Strain reduction)

Global longitudinal strain (GLS) measures how effectively the heart muscle contracts and can detect subtle changes in cardiac function. Nurosym significantly improved GLS compared with placebo stimulation (p=0.001).

3/5

improvement in Blood Vessel Flexibility & improved Circulation (FMD)

mejora

improvement in Blood Vessel Flexibility & improved Circulation (FMD)

Flow-mediated dilation (FMD) measures how effectively an artery widens in response to increased blood flow, indicating endothelial function. Nurosym significantly increased FMD compared with placebo stimulation.

4/5

improvement in markers of Microcirculatory Function

39%

improvement in markers of Microcirculatory Function

Nail-bed blood perfusion measures blood flow through the smallest vessels, indicating microcirculatory function. Perfusion was markedly higher after Nurosym, while placebo stimulation produced little change.

5/5

Research papers (7)

Published November 2022

tVNS increased vagus nerve activity and HRV within minutes

Morning stimulation increased vagus nerve activity by 61%, while HRV improved by 18%. Favourable autonomic effects emerged within the first 10 minutes of stimulation.

Study details
Geng et al. • 40 participants across two studies (24 + 16)
Research institution
Hebei University of Technology
Published 2025

Right-sided tVNS improved cardiovascular reflex control

A brief session improved cardio-vagal baroreflex gain in people with chronic heart failure. This reflex helps the heart respond to changes in blood pressure and is an important measure of cardiovascular control.

Study details
Gentile et al. • 16 participants
Research institution
Scuola Superiore Sant’Anna; Fondazione Toscana Gabriele Monasterio
Published 2023

tVNS strengthened the heart’s electrical signals

In patients undergoing heart surgery, stimulation increased atrial electrical-signal strength during both acute and longer exposure. The findings provide direct evidence that tVNS can influence atrial electrophysiology in real time.

Study details
Kharbanda et al. • 10 participants
Research institution
Erasmus Medical Center
Published 2024

Daily tVNS lowered blood pressure over three months

In young adults with hypertension, diastolic blood pressure fell by 10% following three months of daily stimulation. Systolic blood pressure also decreased progressively throughout the study.

Study details
Mbikyo et al. • 40 participants
Research institution
The First Hospital of China Medical University
Published March 2020

Six months of tVNS dramatically reduced atrial fibrillation burden

In a double-blind, sham-controlled trial, daily stimulation reduced atrial fibrillation burden by 85%. It also lowered TNF-alpha, an inflammatory marker, by 23%.

Study details
Stavrakis et al. • 53 participants
Research institution
University of Oklahoma Health Sciences Center
Published February 2024

Daily tVNS reduced excessive heart-rate rise in POTS

In a randomized, sham-controlled trial, two months of daily stimulation reduced postural heart-rate abnormalities by 45%. The active group also showed better HRV and lower inflammatory activity.

Study details
Stavrakis et al. • 26 participants
Research institution
University of Oklahoma Health Sciences Center
Published August 2025

tVNS reduced frequent premature heartbeats

In a randomized crossover trial, active stimulation reduced the burden of premature ventricular contractions compared with sham. The effect was observed across different origins of the abnormal heartbeats.

Study details
Zafeiropoulos et al. • 36 randomized; 35 analysed
Research institution
Lenox Hill Hospital, Northwell Health; University of Oklahoma Health Sciences Center

Paper details

  • PEER REVIEWED
  • SINGLE-BLIND RANDOMIZED CONTROLLED TRIAL
  • PLACEBO-WAITLIST CONTROLLED
  • N = 70 analyzed; 78 enrolled

Effects of transcutaneous vagus nerve stimulation on subthreshold affective symptoms and perceived stress: findings from a single-blinded randomized trial in community-dwelling adults

  • Anxiety & Stress
Journal
Biological Psychology
Year
2025
Authors
Marta Jackowska¹; Julian Koenig²; Veronika Cibulcova³,⁴; Vera K. Jandackova³,⁴
Population
Non-clinical, community-dwelling adults aged 18 to 75 years. The analyzed sample included 28 men and had a mean age of 49.33 years. People with severe mental, neurological, inflammatory, or cardiovascular conditions were excluded.
Design
Single-blind randomized placebo and waitlist-controlled trial with early active, early sham, late active, and late sham groups. Active stimulation targeted the left tragus and sham stimulation the left earlobe. Participants used the device at home.
Duration
Four weeks total, including two weeks of daily home stimulation for up to four hours per day.

Affiliations

  1. Faculty of Psychology, SWPS University, Poland.
  2. Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  3. Department of Epidemiology and Public Health, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  4. Department of Human Movement Studies, Faculty of Education, University of Ostrava, Ostrava, Czech Republic.

Outcome measures

Primary
Anxiety symptoms measured with GAD-7, depressive symptoms measured with CESD-10, and perceived stress measured with PSS-10.
Secondary
Persistence during the two-week follow-up in early groups, daily adherence, sensitivity analyses accounting for baseline values and regression to the mean, and reported adverse effects.

Summary

Two weeks of active tVNS reduced anxiety symptoms and perceived stress more than sham stimulation in the early intervention groups, with large standardized effects. The findings remained significant in sensitivity analyses accounting for baseline severity and regression to the mean. Active stimulation was not superior to sham for depressive symptoms.

The trial randomized participants to early or late treatment and then to active tragus or sham earlobe stimulation. Participants used the device at home for up to four hours daily, and anxiety, depression, and perceived stress were assessed at baseline, after intervention, and at follow-up. The study design provided both within-person and between-group comparisons.

The result is promising but not fully consistent across the design. Superiority over sham for anxiety and stress appeared in the early phase but not the late phase, and the combined primary contrasts were generally not significant. This means the study supports a potential effect on state-like anxiety and stress more strongly than a definitive, uniformly replicated effect across every randomized group.

The study was not powered through a formal a priori calculation, laboratory staff were not blinded, outcomes were self-reported, and the generally healthy sample may not represent people with diagnosed anxiety disorders. Adherence exceeded the study's reported threshold, and the only adverse complaint was light pain at the electrode site. The research was funded by Czech and European public grants, with funders having no role in the study, and the authors declared no conflicts of interest.

Related studies

Full citation

Jackowska, M., Koenig, J., Cibulcova, V., & Jandackova, V. K. (2025). Effects of transcutaneous vagus nerve stimulation on subthreshold affective symptoms and perceived stress: Findings from a single-blinded randomized trial in community-dwelling adults. Biological Psychology, 202, 109169. https://doi.org/10.1016/j.biopsycho.2025.109169

Paper details

  • PUBLISHED
  • PEER REVIEWED
  • PREREGISTERED RANDOMIZED CONTROLLED TRIAL
  • N = 120

Electroceutical enhancement of self-compassion training using transcutaneous vagus nerve stimulation: results from a preregistered fully factorial randomized controlled trial

  • Anxiety & Stress
Journal
Psychological Medicine
Year
2025
Authors
Sunjeev K. Kamboj, Matthew Peniket, Jessica Norman, Rosalind Robshaw, Amit Soni-Tricker, Caroline Falconer, Paul Gilbert, and Louise Simeonov
Population
120 healthy adults aged 18 to 35 years, balanced by sex and recruited in a non-clinical university setting. Participants receiving current mental-health treatment or living with significant cardiovascular, inflammatory, neurological, or psychiatric conditions were excluded.
Design
Single-site, preregistered, fully factorial randomized controlled trial with four parallel groups: active tVNS plus self-compassion mental-imagery training, active tVNS plus control imagery, sham stimulation plus self-compassion imagery, or sham stimulation plus control imagery.
Duration
Eight daily sessions; approximately 320 minutes of stimulation in total

Affiliations

  1. Clinical Psychopharmacology Unit, University College London, London, United Kingdom
  2. Research Department of Clinical, Educational and Health Psychology, University College London, London, United Kingdom
  3. School of Psychology, College of Health, Psychology and Social Care, University of Derby, Derby, United Kingdom

Outcome measures

Primary
State self-compassion, state self-criticism, and heart-rate variability measured acutely during session 1 and cumulatively across eight sessions.
Secondary
State and trait mindfulness, trait self-compassion, affect, adherence, expectancy, and eye-tracking measures of attention to compassion-expressing faces.

Summary

Pairing active tVNS with self-compassion mental-imagery training was associated with the clearest acute rise in state self-compassion during the first session. The active combination outperformed the other factorial conditions on the primary acute comparison, and state mindfulness showed a similarly rapid pattern. Across repeated sessions, trait self-compassion increased after tVNS but not sham stimulation, while state mindfulness was highest in the combined active condition at the final assessment.

The study randomized 120 healthy adults evenly across four conditions, separating the effects of stimulation from those of the imagery exercise. Active stimulation was delivered to the left tragus and sham stimulation to the left earlobe. Sessions 1 and 8 took place in the laboratory, while sessions 2 to 7 were completed remotely, providing a useful test of both immediate and repeated use across laboratory and home settings.

The findings were specific rather than universal. Self-criticism and compassion-related attentional bias responded to the imagery training, not to stimulation, and neither tVNS nor the imagery condition changed HRV. This suggests that tVNS may influence selected contemplative and self-regulatory outcomes even when a peripheral physiological marker such as HRV does not change.

The study was preregistered and used credible active and sham procedures, with similar expectancy, adherence, and adverse-effect reporting across stimulation groups. Important considerations include the young healthy sample, the exploratory number of outcomes, and the absence of a differential physiological marker of vagal engagement. The Bial Foundation funded the work, Parasym supplied the devices, and the authors declared no competing interests.

Related studies

Full citation

Kamboj, S. K., Peniket, M., Norman, J., Robshaw, R., Soni-Tricker, A., Falconer, C., Gilbert, P., & Simeonov, L. (2025). Electroceutical enhancement of self-compassion training using transcutaneous vagus nerve stimulation: Results from a preregistered fully factorial randomized controlled trial. Psychological Medicine, 55, e223, 1-11. https://doi.org/10.1017/S0033291725101013

Paper details

  • PUBLISHED
  • PEER REVIEWED
  • EXPLORATORY FOUR-ARM PILOT
  • N = 20; 5 per group

Effects of Transcutaneous Vagus Nerve Stimulation, Neurofeedback, and their Combination on Cortisol, Anxiety, and Depression Subtypes in Non-Clinical Adults

  • Anxiety & Stress
Journal
Applied Psychophysiology and Biofeedback
Year
2026
Authors
Seyedeh Zeinab Molaeizadeh, Aitor Aritzeta Galan, and Zahra Zolghadr
Population
20 medication-free university students aged 18 to 24 years, including 19 women and one man, with no neurological, cardiovascular, or psychiatric diagnosis. Baseline symptoms were predominantly subclinical.
Design
Exploratory quasi-experimental pilot with random assignment to neurofeedback, active tVNS, combined neurofeedback plus tVNS, or a no-intervention control. There were no sham neurofeedback or sham tVNS conditions, and analyses focused on within-group change.
Duration
4 weeks; two sessions per week; 30 minutes per tVNS session

Affiliations

  1. Department of Psychology, University of the Basque Country, San Sebastian, Spain
  2. National Center for Health Insurance Research, Tehran, Iran

Outcome measures

Primary
Anxiety and depression-related symptoms measured with the Beck Anxiety Inventory and selected Millon Clinical Multiaxial Inventory IV subscales.
Secondary
Resting EEG alpha/theta ratio and morning salivary cortisol measured before and after the four-week intervention.

Summary

The tVNS-only group showed a significant increase in the EEG alpha/theta ratio, with a large standardized effect. This change was observed in the tVNS group and may reflect an alteration in resting EEG activity, although its functional significance remains uncertain. This provides an exploratory physiological finding, although the small sample and within-group analyses do not establish that tVNS produced a greater EEG change than neurofeedback.

Twenty healthy students were assigned to neurofeedback, tVNS, their combination, or a no-intervention control, with only five people in each group. Active tVNS was delivered to the left tragus with the Parasym device for 30 minutes, twice weekly for four weeks. The study measured anxiety, several depression-related symptom profiles, resting EEG, and morning cortisol before and after the intervention.

The interventions showed different patterns of within-group change. Neurofeedback, not tVNS, was associated with significant reductions in anxiety and a major-depression symptom subscale. Anxiety did not change significantly in the tVNS group, cortisol was unchanged, and combining neurofeedback with tVNS did not add benefit. The evidence therefore supports an exploratory neurophysiological effect of tVNS, not a demonstrated anti-anxiety or cortisol-lowering effect in this study.

The sample was very small, predominantly female, and non-clinical, with no sham-controlled conditions. Several outcomes had missing data, only within-group tests were performed, and the fixed order in the combined group may have introduced fatigue or carryover effects. The authors declared no competing interests; open-access publication support came through the University of the Basque Country.

Related studies

Full citation

Molaeizadeh, S. Z., Aritzeta Galan, A., & Zolghadr, Z. (2026). Effects of transcutaneous vagus nerve stimulation, neurofeedback, and their combination on cortisol, anxiety, and depression subtypes in non-clinical adults. Applied Psychophysiology and Biofeedback. Advance online publication. https://doi.org/10.1007/s10484-025-09764-4

Paper details

  • PUBLISHED
  • PEER REVIEWED
  • RANDOMIZED CONTROLLED PILOT
  • N = 10; 5 taVNS, 5 waitlist control

Transcutaneous auricular vagus nerve stimulation, tolerability, and the Alpha/Theta EEG ratio: a controlled pilot study relevant to emotion regulation

  • Anxiety & Stress
Journal
Frontiers in Psychiatry
Year
2026
Authors
Seyedeh Zeinab Molaeizadeh, Aitor Aritzeta, Weronika Górska and Seyyedeh Fatemeh Molaeezadeh
Population
10 healthy female university students aged 18 to 24, with an average age of 21.1 years. Participants had no neurological, psychiatric or cardiovascular conditions, were not taking psychotropic medication and had normal sensory function.
Design
A randomized, waitlist-controlled pilot study comparing changes in the taVNS group with those in the control group over time.
Duration
4 weeks, with EEG reassessed one week after the eighth session

Affiliations

  1. Department of Psychology, University of the Basque Country, San Sebastian, Spain
  2. Department of Chemistry, Warsaw University of Technology, Warsaw, Poland
  3. Department of Electrical and Computer Engineering, Jundi-Shapur University of Technology, Dezful, Iran

Outcome measures

Primary
Resting-state Alpha/Theta EEG ratio measured at the central Cz electrode, feasibility and tolerability, including completion, adverse events and stimulation-related observations.
Secondary
Theta/Beta EEG ratio, the relationship between stimulation intensity and EEG change, and subjective sensations of pulse change.

Summary

This controlled pilot investigated whether a four-week course of transcutaneous auricular vagus nerve stimulation could change resting brain activity patterns relevant to emotion regulation. Ten healthy women were randomized to either eight sessions of taVNS or a waitlist control group.

The change in the Alpha/Theta EEG ratio was significantly greater in the taVNS group than in the control group. The ratio increased in all five stimulated participants, while the control group showed little overall change. The active group recorded an average increase of 25.8%, although this change was not statistically significant when the active group was considered alone. The key statistical finding was the between-group difference, which remained significant after correction for multiple comparisons.

All ten participants completed the protocol, and all 40 planned stimulation sessions were delivered. No serious adverse events, withdrawals or treatment discontinuations occurred. Most reported effects were mild skin sensations, with one headache and one episode of dizziness. These findings show that the protocol was feasible to deliver in this small group, but the sample is too small to establish a wider safety profile.

The study provides an early neurophysiological signal that taVNS may influence a resting EEG measure of interest for future emotion-regulation research. It does not show that taVNS reduced anxiety or improved emotional regulation, since the researchers did not collect anxiety scores, behavioural outcomes, autonomic measures or clinical symptom data. The exploratory Theta/Beta result should not be presented as a benefit because it moved in a direction the authors describe as generally unfavourable.

The findings should also be interpreted in light of the very small sample, the absence of an active sham, the use of a single EEG recording site and the lack of prospective trial registration. Several analyses were selected after the data had been inspected. Parasym supplied the device, advised on stimulation parameters and covered the article-processing charge, and one author reported consulting for Parasym Scientific Ltd.

Related studies

Full citation

Molaeizadeh, S. Z., Aritzeta, A., Górska, W., & Molaeezadeh, S. F. (2026). Transcutaneous auricular vagus nerve stimulation, tolerability, and the Alpha/Theta EEG ratio: A controlled pilot study relevant to emotion regulation. Frontiers in Psychiatry, 17, 1912977. https://doi.org/10.3389/fpsyt.2026.1912977 Read the full paper

Paper details

  • PEER REVIEWED
  • OPEN-LABEL PILOT
  • N = 20

Transcutaneous Auricular Vagus Nerve Stimulation (tVNS) can Reverse the Manifestations of the Long-COVID Syndrome: A Pilot Study

  • Anxiety & Stress
  • Sleep
  • Fatigue & Energy
  • Gut Health
  • Pain & Inflammation
  • Focus, memory & cognitive performance
Journal
Advances in Neurology and Neuroscience Research
Year
2021
Authors
Paul Verbanck, Anne-Marie Clarinval, Francis Burton, Frédéric Corazza, Carole Nagant, Guy Cheron
Population
Twenty adults aged 20 to 59 years with persistent Long COVID symptoms for at least 12 weeks; 12 were women and 8 were men.
Design
Prospective, single-arm, open-label pilot using individualized symptom profiles and repeated assessments.
Duration
10 consecutive daily sessions with a 7-day post-treatment follow-up

Affiliations

  1. Laboratory of Neurophysiology and Movement Biomechanics, Université Libre de Bruxelles, Belgium
  2. Human Waves c/o PsyPluriel, Brussels, Belgium
  3. Laboratory of Translational Research, Centre Hospitalier Universitaire Brugmann, Université Libre de Bruxelles, Belgium

Outcome measures

Primary
Change in an individualized composite symptom-severity score covering each participant's Long COVID manifestations.
Secondary
Pichot Fatigue Scale, Beck Depression Inventory, grip strength, blood oxygen saturation, circulating inflammatory markers, completion and side effects.

Summary

Across ten daily sessions, participants reported improvements in several symptoms, including fatigue, low mood, brain fog and gastrointestinal complaints. The study reported reductions of 48%, 45% and 40% in fatigue, low mood and brain fog, respectively, and an 80% improvement in gastrointestinal symptoms. The individualized composite symptom-severity score improved significantly by day 10, with improvement still observed at the seven-day follow-up.

Twenty adults with persistent Long COVID received daily left-tragus stimulation and were assessed at baseline, day 5, day 10 and one week later. The study captured the multisystem nature of Long COVID through individualized symptom scales, while also measuring fatigue, depressive symptoms, grip strength, blood oxygen saturation and a panel of inflammatory biomarkers.

Clinical improvement emerged across fatigue, pain, digestive complaints and cognitive difficulties, with fatigue and low mood also improving on established questionnaires. All participants completed the study, and most reported no side effect. Circulating inflammatory markers did not change, weakening the researchers' original inflammation hypothesis and shifting their interpretation toward autonomic regulation rather than a detectable change in peripheral inflammation.

This was an uncontrolled, open-label pilot in only 20 participants, so expectancy effects, symptom fluctuation and natural recovery remain plausible explanations. The primary outcome was a personalized composite rather than a validated Long COVID scale, and infection confirmation was mixed because testing was limited early in the pandemic. The study was supported by the Public Service of Wallonia and the Cerveau et Société Foundation; the authors declared no conflicts of interest.

Related studies

Full citation

Verbanck, P., Clarinval, A. M., Burton, F., Corazza, F., Nagant, C., & Cheron, G. (2021). Transcutaneous auricular vagus nerve stimulation (tVNS) can reverse the manifestations of the Long-COVID syndrome: A pilot study. Advances in Neurology and Neuroscience Research, 2, 100011. https://doi.org/10.51956/ANNR.100011

Paper details

  • PEER REVIEWED
  • OPEN-LABEL PILOT
  • N = 24

Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: a pilot study

  • Anxiety & Stress
  • Sleep
  • Fatigue & Energy
  • Focus, memory & cognitive performance
Journal
Frontiers in Neurology
Year
2024
Authors
Zhong Sheng Zheng, Ninette Simonian, Jing Wang, Emily R. Rosario
Population
Twenty-four women with persistent Long COVID and cognitive impairment, with a mean age of 45.8 years and symptoms lasting an average of 20.2 months after infection.
Design
Prospective, single-group, open-label pilot with baseline, post-intervention and 1-month follow-up assessments.
Duration
10 days of at-home treatment, 30 minutes twice daily, with 1-month follow-up

Affiliations

  1. Research Institute, Casa Colina Hospital and Centers for Healthcare, Pomona, California, United States
  2. Institute of Advanced Consciousness Studies, Santa Monica, California, United States

Outcome measures

Primary
Fluid cognition and its component domains measured with the NIH Toolbox, including attention, processing speed, episodic memory, working memory and executive function.
Secondary
Anxiety, depression, sleep disturbance, fatigue and olfactory function measured with validated instruments.

Summary

After ten days of at-home treatment, the approved evidence summary reports an 11% improvement in attention and a 35% reduction in anxiety. Participants also improved in overall fluid cognition, processing speed, episodic memory, depression and sleep, with gains maintained or continuing to develop at the one-month follow-up.

Twenty-four women with longstanding Long COVID used the Parasym AVNT system for 30 minutes twice daily over ten consecutive days. Cognition was the primary outcome and was assessed with NIH Toolbox measures, while anxiety, depression, fatigue, sleep and smell were tracked as secondary outcomes at baseline, immediately after treatment and one month later.

The cognitive signal spanned several domains rather than a single test. Fatigue improved more slowly and reached statistical significance only at one month, while smell did not change. Six participants completed follow-up remotely, so only 18 had complete data for some cognitive and olfactory measures, although episodic and working-memory data were available for all 24.

The absence of a control group means the study cannot rule out placebo effects, repeated-testing effects, symptom fluctuation or spontaneous recovery. The cohort was small and all female, and a small amount of missing questionnaire data was imputed. The Norris Foundation supported the work, and the authors declared no commercial or financial conflicts of interest.

Related studies

Full citation

Zheng, Z. S., Simonian, N., Wang, J., & Rosario, E. R. (2024). Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: A pilot study. Frontiers in Neurology, 15, 1393371. https://doi.org/10.3389/fneur.2024.1393371

Paper details

  • PEER REVIEWED
  • SINGLE-ARM PILOT STUDY
  • FIBROMYALGIA
  • N = 18 enrolled; 17 completed

Vagal nerve stimulation and fibromyalgia: an additional therapeutic option

  • Sleep
  • Pain & Inflammation
Journal
Clinical and Experimental Rheumatology
Year
2025
Authors
Giulio Dolcini¹; Martina Favretti¹; Daniele Franculli²; Giorgia Buoncuore³; Greta Pellegrino⁴,⁵; Marco Di Carlo⁶; Piercarlo Sarzi-Puttini⁴,⁵; Fabrizio Conti³; Cristina Iannuccelli⁷; Manuela Di Franco³
Population
Adults aged 18 to 65 years with fibromyalgia diagnosed using the 2016 American College of Rheumatology criteria and receiving stable pharmacological and non-pharmacological treatment for at least three months.
Design
Longitudinal, single-center, open-label pilot study with a single treatment group and no sham control.
Duration
Four weeks of treatment, followed by a four-week post-treatment assessment.

Affiliations

  1. Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
  2. Department of Medicine, Acquapendente Civil Hospital, Acquapendente, Italy.
  3. Department of Internal Clinical, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  4. Department of Rheumatology, IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy.
  5. Department of Biochemical and Clinical Sciences, University of Milan, Milan, Italy.
  6. Rheumatology Unit, Carlo Urbani Hospital, Universita Politecnica delle Marche, Jesi, Italy.
  7. Rheumatology Unit, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.

Outcome measures

Primary
Fibromyalgia disease severity and pain, assessed with the Widespread Pain Index, revised Fibromyalgia Impact Questionnaire, Symptom Severity Scale, and pain visual analogue scale.
Secondary
Sleep quality measured with the Pittsburgh Sleep Quality Index, serum brain-derived neurotrophic factor, persistence of effects after treatment, tolerability, and participant satisfaction.

Summary

Four weeks of AVNT treatment was associated with a 38% reduction in widespread pain and a 30% improvement in sleep quality from baseline. Fibromyalgia burden also improved across the revised Fibromyalgia Impact Questionnaire total score, overall impact, and symptom components. An improvement in the Widespread Pain Index was already detectable after two weeks, suggesting that symptom change began before the full treatment course was complete.

Eighteen adults with fibromyalgia received 30 minutes of stimulation, five days a week, for four consecutive weeks while keeping their existing treatment stable. Seventeen completed the protocol. At the end of treatment, 11 of the 17 participants who completed the study no longer met the study's stated 2016 diagnostic criteria for fibromyalgia. Most participants also reported that they would repeat the treatment or recommend it to others.

Pain intensity on the visual analogue scale, physical-function and Symptom Severity Scale measures, and serum brain-derived neurotrophic factor did not change significantly. At the four-week post-treatment visit, most disease-severity and sleep scores had moved back toward baseline, although the overall-impact component remained improved. The results therefore provide stronger support for benefits during the treatment period than for a durable post-treatment effect.

This was a small open-label pilot without a sham group, so expectancy effects and natural symptom fluctuation cannot be ruled out. Mild adverse effects were common, but no serious or unexpected reactions occurred and only one participant stopped early for a reason unrelated to the study. Medical writing was funded through a donation from AbbVie Srl, and the authors declared no competing interests. Larger controlled studies are warranted to further evaluate efficacy and determine the optimal duration of treatment.

Related studies

Full citation

Dolcini, G., Favretti, M., Franculli, D., Buoncuore, G., Pellegrino, G., Di Carlo, M., Sarzi-Puttini, P., Conti, F., Iannuccelli, C., & Di Franco, M. (2025). Vagal nerve stimulation and fibromyalgia: An additional therapeutic option. Clinical and Experimental Rheumatology, 43(6), 1095-1104. https://doi.org/10.55563/clinexprheumatol/johqvo

Paper details

  • PEER REVIEWED
  • SHAM-CONTROLLED FIELD STUDY
  • N = 48

The effect of transcutaneous auricular vagus nerve stimulation on vigilance, cognition, and mood during military exercise with acute sleep deprivation

  • Fatigue & Energy
  • Focus, memory & cognitive performance
Journal
Cognitive Research: Principles and Implications
Year
2026
Authors
Tomi Passi, Johanna Närväinen, Kristian Lukander, Jari Laarni, Mikko Lindholm, Kati Pettersson, Saija Mauno, Satu Pakarinen
Population
Forty-eight healthy male special border Jaeger conscripts aged 19 to 25 years participating in military training that included 24 hours of total sleep deprivation.
Design
Participant-blinded, pseudorandomly allocated active-versus-ramp-down-sham field study conducted during military training.
Duration
Single 4-minute stimulation session, followed by repeated testing through 7 a.m. after a night without sleep

Affiliations

  1. Finnish Institute of Occupational Health, Helsinki, Finland
  2. VTT Technical Research Centre of Finland Ltd, Espoo, Finland
  3. Faculty of Social Sciences, Psychology, Tampere University, Tampere, Finland
  4. Department of Psychology, University of Jyväskylä, Jyväskylä, Finland

Outcome measures

Primary
Vigilance measured repeatedly with the Psychomotor Vigilance Task, including median reaction time across the night and during the early-morning circadian low point.
Secondary
Sustained attention and response inhibition on the Sustained Attention to Response Task, emotional valence and self-reported sleepiness.

Summary

During the early-morning period of greatest vulnerability to sleep-loss-related slowing, higher stimulation intensity was associated with better preservation of vigilance. The relationship emerged at 5 a.m. and 7 a.m. on the monotonous Psychomotor Vigilance Task, when sleep-loss-related slowing was greatest. Higher stimulation intensity was also associated with a smaller shift toward negative emotional valence after the response-inhibition task.

Forty-eight healthy military conscripts participated in the field study, with 24 allocated to active stimulation and 24 to a ramp-down sham that decreased to zero during the first minute. A single four-minute session was administered in the evening, followed by repeated vigilance testing at two-hour intervals across a night of enforced wakefulness. Testing took place during real military training rather than under tightly controlled laboratory conditions.

The result was specific rather than universal. Stimulation did not improve response inhibition on the more engaging go/no-go task, and it did not produce a clear effect on sleepiness or emotional valence measured after the vigilance task. The key signal was an intensity-dependent association with preserved performance on a simple, repetitive vigilance task during the early-morning vulnerability window, rather than a broad enhancement of cognitive performance.

The study involved a relatively small group of young, fit men, used pseudorandom allocation, did not formally assess the success of blinding, and had considerable uncertainty around some estimates. It also lacked sleep data from the preceding night. The Finnish Defence Forces funded the research, and the authors declared no competing interests.

Related studies

Full citation

Passi, T., Närväinen, J., Lukander, K., Laarni, J., Lindholm, M., Pettersson, K., Mauno, S., & Pakarinen, S. (2026). The effect of transcutaneous auricular vagus nerve stimulation on vigilance, cognition, and mood during military exercise with acute sleep deprivation. Cognitive Research: Principles and Implications, 11, 32. https://doi.org/10.1186/s41235-026-00730-0

Paper details

  • PEER REVIEWED
  • OPEN-LABEL PILOT
  • N = 20

Transcutaneous Auricular Vagus Nerve Stimulation (tVNS) can Reverse the Manifestations of the Long-COVID Syndrome: A Pilot Study

  • Anxiety & Stress
  • Sleep
  • Fatigue & Energy
  • Gut Health
  • Pain & Inflammation
  • Focus, memory & cognitive performance
Journal
Advances in Neurology and Neuroscience Research
Year
2021
Authors
Paul Verbanck, Anne-Marie Clarinval, Francis Burton, Frédéric Corazza, Carole Nagant, Guy Cheron
Population
Twenty adults aged 20 to 59 years with persistent Long COVID symptoms for at least 12 weeks; 12 were women and 8 were men.
Design
Prospective, single-arm, open-label pilot using individualized symptom profiles and repeated assessments.
Duration
10 consecutive daily sessions with a 7-day post-treatment follow-up

Affiliations

  1. Laboratory of Neurophysiology and Movement Biomechanics, Université Libre de Bruxelles, Belgium
  2. Human Waves c/o PsyPluriel, Brussels, Belgium
  3. Laboratory of Translational Research, Centre Hospitalier Universitaire Brugmann, Université Libre de Bruxelles, Belgium

Outcome measures

Primary
Change in an individualized composite symptom-severity score covering each participant's Long COVID manifestations.
Secondary
Pichot Fatigue Scale, Beck Depression Inventory, grip strength, blood oxygen saturation, circulating inflammatory markers, completion and side effects.

Summary

Across ten daily sessions, participants reported improvements in several symptoms, including fatigue, low mood, brain fog and gastrointestinal complaints. The study reported reductions of 48%, 45% and 40% in fatigue, low mood and brain fog, respectively, and an 80% improvement in gastrointestinal symptoms. The individualized composite symptom-severity score improved significantly by day 10, with improvement still observed at the seven-day follow-up.

Twenty adults with persistent Long COVID received daily left-tragus stimulation and were assessed at baseline, day 5, day 10 and one week later. The study captured the multisystem nature of Long COVID through individualized symptom scales, while also measuring fatigue, depressive symptoms, grip strength, blood oxygen saturation and a panel of inflammatory biomarkers.

Clinical improvement emerged across fatigue, pain, digestive complaints and cognitive difficulties, with fatigue and low mood also improving on established questionnaires. All participants completed the study, and most reported no side effect. Circulating inflammatory markers did not change, weakening the researchers' original inflammation hypothesis and shifting their interpretation toward autonomic regulation rather than a detectable change in peripheral inflammation.

This was an uncontrolled, open-label pilot in only 20 participants, so expectancy effects, symptom fluctuation and natural recovery remain plausible explanations. The primary outcome was a personalized composite rather than a validated Long COVID scale, and infection confirmation was mixed because testing was limited early in the pandemic. The study was supported by the Public Service of Wallonia and the Cerveau et Société Foundation; the authors declared no conflicts of interest.

Related studies

Full citation

Verbanck, P., Clarinval, A. M., Burton, F., Corazza, F., Nagant, C., & Cheron, G. (2021). Transcutaneous auricular vagus nerve stimulation (tVNS) can reverse the manifestations of the Long-COVID syndrome: A pilot study. Advances in Neurology and Neuroscience Research, 2, 100011. https://doi.org/10.51956/ANNR.100011

Paper details

  • PEER REVIEWED
  • OPEN-LABEL PILOT
  • N = 15 evaluable (17 enrolled)

Transcutaneous Vagus Nerve Stimulation in the Treatment of Long Covid-Chronic Fatigue Syndrome

  • Fatigue & Energy
  • Pain & Inflammation
Journal
Archives of Clinical and Biomedical Research
Year
2023
Authors
Benjamin H. Natelson, Michelle Blate, Tiffany Soto
Population
Adults with persistent symptoms for at least 6 months after COVID-19 who met the 1994 case definition for chronic fatigue syndrome; 15 participants provided evaluable data.
Design
Prospective, single-arm, open-label pilot with prespecified individual and cohort-level response criteria.
Duration
6 weeks of daily at-home stimulation

Affiliations

  1. Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, United States

Outcome measures

Primary
A prespecified composite response requiring improvement in at least two of four domains: SF-36 physical function, the participant's most troubling symptom, Chalder fatigue caseness, and Patient Global Impression of Change. The study was considered successful if it passed its prespecified cohort-level response threshold.
Secondary
A 10-point or greater improvement on the Profile of Mood States, plus safety and tolerability monitoring during fortnightly calls.

Summary

Eight of the 15 evaluable participants met the prespecified composite response criteria after six weeks of treatment, meeting the study's predefined threshold for cohort-level success. The most prominent improvements were in participants' global impressions of change and their most troubling symptom, with additional improvements in fatigue status and physical function. Brain fog did not improve in any participant, an important boundary on the result.

Seventeen adults with Long COVID who also met the study's criteria for chronic fatigue syndrome entered this pragmatic pilot. Participants used left-tragus stimulation at home for 35 minutes each day while continuing their existing medications, and the study assessed physical function, fatigue, widespread pain, brain fog, mood and perceived change. Two participants were lost to follow-up, leaving 15 in the evaluable cohort.

The prespecified composite required improvement across multiple domains, providing a broader assessment of response than any single questionnaire score. Five participants also met the secondary mood criterion, and no adverse events were reported during the six-week study. Together, the results support a larger controlled trial in a carefully defined Long COVID subgroup.

This was a small open-label pilot without a sham group, so placebo effects, regression to the mean and natural symptom fluctuation cannot be separated from treatment effects. The work was supported by donations from Dr Natelson's patients, and the manufacturer donated the devices. The authors called for a sham-controlled follow-up study before drawing firm conclusions about efficacy.

Related studies

Full citation

Natelson, B. H., Blate, M., & Soto, T. (2023). Transcutaneous vagus nerve stimulation in the treatment of Long Covid-chronic fatigue syndrome. Archives of Clinical and Biomedical Research, 7(2), 239-241. https://doi.org/10.26502/acbr.50170337

Paper details

  • PEER REVIEWED
  • OPEN-LABEL PILOT
  • N = 24

Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: a pilot study

  • Anxiety & Stress
  • Sleep
  • Fatigue & Energy
  • Focus, memory & cognitive performance
Journal
Frontiers in Neurology
Year
2024
Authors
Zhong Sheng Zheng, Ninette Simonian, Jing Wang, Emily R. Rosario
Population
Twenty-four women with persistent Long COVID and cognitive impairment, with a mean age of 45.8 years and symptoms lasting an average of 20.2 months after infection.
Design
Prospective, single-group, open-label pilot with baseline, post-intervention and 1-month follow-up assessments.
Duration
10 days of at-home treatment, 30 minutes twice daily, with 1-month follow-up

Affiliations

  1. Research Institute, Casa Colina Hospital and Centers for Healthcare, Pomona, California, United States
  2. Institute of Advanced Consciousness Studies, Santa Monica, California, United States

Outcome measures

Primary
Fluid cognition and its component domains measured with the NIH Toolbox, including attention, processing speed, episodic memory, working memory and executive function.
Secondary
Anxiety, depression, sleep disturbance, fatigue and olfactory function measured with validated instruments.

Summary

After ten days of at-home treatment, the approved evidence summary reports an 11% improvement in attention and a 35% reduction in anxiety. Participants also improved in overall fluid cognition, processing speed, episodic memory, depression and sleep, with gains maintained or continuing to develop at the one-month follow-up.

Twenty-four women with longstanding Long COVID used the Parasym AVNT system for 30 minutes twice daily over ten consecutive days. Cognition was the primary outcome and was assessed with NIH Toolbox measures, while anxiety, depression, fatigue, sleep and smell were tracked as secondary outcomes at baseline, immediately after treatment and one month later.

The cognitive signal spanned several domains rather than a single test. Fatigue improved more slowly and reached statistical significance only at one month, while smell did not change. Six participants completed follow-up remotely, so only 18 had complete data for some cognitive and olfactory measures, although episodic and working-memory data were available for all 24.

The absence of a control group means the study cannot rule out placebo effects, repeated-testing effects, symptom fluctuation or spontaneous recovery. The cohort was small and all female, and a small amount of missing questionnaire data was imputed. The Norris Foundation supported the work, and the authors declared no commercial or financial conflicts of interest.

Related studies

Full citation

Zheng, Z. S., Simonian, N., Wang, J., & Rosario, E. R. (2024). Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: A pilot study. Frontiers in Neurology, 15, 1393371. https://doi.org/10.3389/fneur.2024.1393371

Paper details

  • PEER REVIEWED
  • OPEN-LABEL PILOT
  • N = 20

Transcutaneous Auricular Vagus Nerve Stimulation (tVNS) can Reverse the Manifestations of the Long-COVID Syndrome: A Pilot Study

  • Anxiety & Stress
  • Sleep
  • Fatigue & Energy
  • Gut Health
  • Pain & Inflammation
  • Focus, memory & cognitive performance
Journal
Advances in Neurology and Neuroscience Research
Year
2021
Authors
Paul Verbanck, Anne-Marie Clarinval, Francis Burton, Frédéric Corazza, Carole Nagant, Guy Cheron
Population
Twenty adults aged 20 to 59 years with persistent Long COVID symptoms for at least 12 weeks; 12 were women and 8 were men.
Design
Prospective, single-arm, open-label pilot using individualized symptom profiles and repeated assessments.
Duration
10 consecutive daily sessions with a 7-day post-treatment follow-up

Affiliations

  1. Laboratory of Neurophysiology and Movement Biomechanics, Université Libre de Bruxelles, Belgium
  2. Human Waves c/o PsyPluriel, Brussels, Belgium
  3. Laboratory of Translational Research, Centre Hospitalier Universitaire Brugmann, Université Libre de Bruxelles, Belgium

Outcome measures

Primary
Change in an individualized composite symptom-severity score covering each participant's Long COVID manifestations.
Secondary
Pichot Fatigue Scale, Beck Depression Inventory, grip strength, blood oxygen saturation, circulating inflammatory markers, completion and side effects.

Summary

Across ten daily sessions, participants reported improvements in several symptoms, including fatigue, low mood, brain fog and gastrointestinal complaints. The study reported reductions of 48%, 45% and 40% in fatigue, low mood and brain fog, respectively, and an 80% improvement in gastrointestinal symptoms. The individualized composite symptom-severity score improved significantly by day 10, with improvement still observed at the seven-day follow-up.

Twenty adults with persistent Long COVID received daily left-tragus stimulation and were assessed at baseline, day 5, day 10 and one week later. The study captured the multisystem nature of Long COVID through individualized symptom scales, while also measuring fatigue, depressive symptoms, grip strength, blood oxygen saturation and a panel of inflammatory biomarkers.

Clinical improvement emerged across fatigue, pain, digestive complaints and cognitive difficulties, with fatigue and low mood also improving on established questionnaires. All participants completed the study, and most reported no side effect. Circulating inflammatory markers did not change, weakening the researchers' original inflammation hypothesis and shifting their interpretation toward autonomic regulation rather than a detectable change in peripheral inflammation.

This was an uncontrolled, open-label pilot in only 20 participants, so expectancy effects, symptom fluctuation and natural recovery remain plausible explanations. The primary outcome was a personalized composite rather than a validated Long COVID scale, and infection confirmation was mixed because testing was limited early in the pandemic. The study was supported by the Public Service of Wallonia and the Cerveau et Société Foundation; the authors declared no conflicts of interest.

Related studies

Full citation

Verbanck, P., Clarinval, A. M., Burton, F., Corazza, F., Nagant, C., & Cheron, G. (2021). Transcutaneous auricular vagus nerve stimulation (tVNS) can reverse the manifestations of the Long-COVID syndrome: A pilot study. Advances in Neurology and Neuroscience Research, 2, 100011. https://doi.org/10.51956/ANNR.100011

Paper details

  • PEER REVIEWED
  • RANDOMIZED CONTROLLED TRIAL
  • SINGLE BLIND
  • N = 76

Influence of a 2-week transcutaneous auricular vagus nerve stimulation on memory: findings from a randomized placebo controlled trial in non-clinical adults

  • Focus, memory & cognitive performance
Journal
Clinical Autonomic Research
Year
2024
Authors
Veronika Cibulcova¹,²; Julian Koenig³; Marta Jackowska⁴; Vera Kr Jandackova¹,²
Population
76 non-clinical adults aged 18 to 75 years, including 30 men, with a mean age of 48.32 years.
Design
Single-blind, randomized, placebo-waitlist controlled trial with four groups: early active, early sham, late active, and late sham stimulation. Active stimulation was applied to the left tragus and sham stimulation to the left earlobe. The intervention was self-administered at home.
Duration
Four weeks total, including two weeks of daily stimulation for up to four hours per day.

Affiliations

  1. Department of Epidemiology and Public Health, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  2. Department of Human Movement Studies, Faculty of Education, University of Ostrava, Ostrava, Czech Republic.
  3. Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  4. Faculty of Psychology, SWPS University, Sopot, Poland.

Outcome measures

Primary
Immediate recall, short-term verbal memory, and delayed recall, assessed with the Rey Auditory Verbal Learning Test.
Secondary
Persistence of any memory changes at follow-up, adherence to home stimulation, and reported harms or side effects.

Summary

This randomized study examined whether two weeks of daily transcutaneous auricular vagus nerve stimulation could improve verbal memory in 76 non-clinical adults. Participants used the Nurosym device at home for up to four hours per day. Active stimulation was delivered at the left tragus, while sham stimulation was delivered at the left earlobe to produce a similar sensation without targeting the auricular vagus nerve.

Active stimulation improved immediate recall and short-term memory in both the early and late treatment groups. The improvement in immediate recall was significantly greater with active stimulation than with sham in both treatment phases. Improvements achieved by the early active group were also maintained during the subsequent two-week follow-up. Delayed recall did not improve, which the researchers suggest may partly reflect participants already scoring close to the test’s maximum.

The design provides greater confidence than an uncontrolled study because participants were randomized, blinded to whether they received active or sham stimulation, and assessed using three alternative versions of a standardized memory test. The result was reproduced across two separate treatment windows, and the immediate-recall finding remained after accounting for medication use and existing health conditions.

The study was single-blinded and stimulation was self-administered, which potentially affected consistency. The sample was also generally healthy, so the findings cannot automatically be extended to people with cognitive impairment or dementia. No formal sample-size calculation was conducted before the trial. However, adherence was high, no serious side effects were reported, and sensitivity analyses supported the main immediate-recall result. The authors reported no conflicts of interest, and the research was supported by Czech public research programmes.

Related studies

Full citation

Cibulcova, V., Koenig, J., Jackowska, M., & Jandackova, V. K. (2024). Influence of a 2-week transcutaneous auricular vagus nerve stimulation on memory: Findings from a randomized placebo controlled trial in non-clinical adults. Clinical Autonomic Research, 34(4), 447-462. https://doi.org/10.1007/s10286-024-01053-0

Paper details

  • PUBLISHED
  • PEER REVIEWED
  • PREREGISTERED RANDOMIZED CONTROLLED TRIAL
  • N = 120

Electroceutical enhancement of self-compassion training using transcutaneous vagus nerve stimulation: results from a preregistered fully factorial randomized controlled trial

  • Anxiety & Stress
Journal
Psychological Medicine
Year
2025
Authors
Sunjeev K. Kamboj, Matthew Peniket, Jessica Norman, Rosalind Robshaw, Amit Soni-Tricker, Caroline Falconer, Paul Gilbert, and Louise Simeonov
Population
120 healthy adults aged 18 to 35 years, balanced by sex and recruited in a non-clinical university setting. Participants receiving current mental-health treatment or living with significant cardiovascular, inflammatory, neurological, or psychiatric conditions were excluded.
Design
Single-site, preregistered, fully factorial randomized controlled trial with four parallel groups: active tVNS plus self-compassion mental-imagery training, active tVNS plus control imagery, sham stimulation plus self-compassion imagery, or sham stimulation plus control imagery.
Duration
Eight daily sessions; approximately 320 minutes of stimulation in total

Affiliations

  1. Clinical Psychopharmacology Unit, University College London, London, United Kingdom
  2. Research Department of Clinical, Educational and Health Psychology, University College London, London, United Kingdom
  3. School of Psychology, College of Health, Psychology and Social Care, University of Derby, Derby, United Kingdom

Outcome measures

Primary
State self-compassion, state self-criticism, and heart-rate variability measured acutely during session 1 and cumulatively across eight sessions.
Secondary
State and trait mindfulness, trait self-compassion, affect, adherence, expectancy, and eye-tracking measures of attention to compassion-expressing faces.

Summary

Pairing active tVNS with self-compassion mental-imagery training was associated with the clearest acute rise in state self-compassion during the first session. The active combination outperformed the other factorial conditions on the primary acute comparison, and state mindfulness showed a similarly rapid pattern. Across repeated sessions, trait self-compassion increased after tVNS but not sham stimulation, while state mindfulness was highest in the combined active condition at the final assessment.

The study randomized 120 healthy adults evenly across four conditions, separating the effects of stimulation from those of the imagery exercise. Active stimulation was delivered to the left tragus and sham stimulation to the left earlobe. Sessions 1 and 8 took place in the laboratory, while sessions 2 to 7 were completed remotely, providing a useful test of both immediate and repeated use across laboratory and home settings.

The findings were specific rather than universal. Self-criticism and compassion-related attentional bias responded to the imagery training, not to stimulation, and neither tVNS nor the imagery condition changed HRV. This suggests that tVNS may influence selected contemplative and self-regulatory outcomes even when a peripheral physiological marker such as HRV does not change.

The study was preregistered and used credible active and sham procedures, with similar expectancy, adherence, and adverse-effect reporting across stimulation groups. Important considerations include the young healthy sample, the exploratory number of outcomes, and the absence of a differential physiological marker of vagal engagement. The Bial Foundation funded the work, Parasym supplied the devices, and the authors declared no competing interests.

Related studies

Full citation

Kamboj, S. K., Peniket, M., Norman, J., Robshaw, R., Soni-Tricker, A., Falconer, C., Gilbert, P., & Simeonov, L. (2025). Electroceutical enhancement of self-compassion training using transcutaneous vagus nerve stimulation: Results from a preregistered fully factorial randomized controlled trial. Psychological Medicine, 55, e223, 1-11. https://doi.org/10.1017/S0033291725101013

Paper details

  • PEER REVIEWED
  • OPEN-LABEL PILOT
  • N = 15 evaluable (17 enrolled)

Transcutaneous Vagus Nerve Stimulation in the Treatment of Long Covid-Chronic Fatigue Syndrome

  • Fatigue & Energy
  • Pain & Inflammation
Journal
Archives of Clinical and Biomedical Research
Year
2023
Authors
Benjamin H. Natelson, Michelle Blate, Tiffany Soto
Population
Adults with persistent symptoms for at least 6 months after COVID-19 who met the 1994 case definition for chronic fatigue syndrome; 15 participants provided evaluable data.
Design
Prospective, single-arm, open-label pilot with prespecified individual and cohort-level response criteria.
Duration
6 weeks of daily at-home stimulation

Affiliations

  1. Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, United States

Outcome measures

Primary
A prespecified composite response requiring improvement in at least two of four domains: SF-36 physical function, the participant's most troubling symptom, Chalder fatigue caseness, and Patient Global Impression of Change. The study was considered successful if it passed its prespecified cohort-level response threshold.
Secondary
A 10-point or greater improvement on the Profile of Mood States, plus safety and tolerability monitoring during fortnightly calls.

Summary

Eight of the 15 evaluable participants met the prespecified composite response criteria after six weeks of treatment, meeting the study's predefined threshold for cohort-level success. The most prominent improvements were in participants' global impressions of change and their most troubling symptom, with additional improvements in fatigue status and physical function. Brain fog did not improve in any participant, an important boundary on the result.

Seventeen adults with Long COVID who also met the study's criteria for chronic fatigue syndrome entered this pragmatic pilot. Participants used left-tragus stimulation at home for 35 minutes each day while continuing their existing medications, and the study assessed physical function, fatigue, widespread pain, brain fog, mood and perceived change. Two participants were lost to follow-up, leaving 15 in the evaluable cohort.

The prespecified composite required improvement across multiple domains, providing a broader assessment of response than any single questionnaire score. Five participants also met the secondary mood criterion, and no adverse events were reported during the six-week study. Together, the results support a larger controlled trial in a carefully defined Long COVID subgroup.

This was a small open-label pilot without a sham group, so placebo effects, regression to the mean and natural symptom fluctuation cannot be separated from treatment effects. The work was supported by donations from Dr Natelson's patients, and the manufacturer donated the devices. The authors called for a sham-controlled follow-up study before drawing firm conclusions about efficacy.

Related studies

Full citation

Natelson, B. H., Blate, M., & Soto, T. (2023). Transcutaneous vagus nerve stimulation in the treatment of Long Covid-chronic fatigue syndrome. Archives of Clinical and Biomedical Research, 7(2), 239-241. https://doi.org/10.26502/acbr.50170337

Paper details

  • PEER REVIEWED
  • SHAM-CONTROLLED FIELD STUDY
  • N = 48

The effect of transcutaneous auricular vagus nerve stimulation on vigilance, cognition, and mood during military exercise with acute sleep deprivation

  • Fatigue & Energy
  • Focus, memory & cognitive performance
Journal
Cognitive Research: Principles and Implications
Year
2026
Authors
Tomi Passi, Johanna Närväinen, Kristian Lukander, Jari Laarni, Mikko Lindholm, Kati Pettersson, Saija Mauno, Satu Pakarinen
Population
Forty-eight healthy male special border Jaeger conscripts aged 19 to 25 years participating in military training that included 24 hours of total sleep deprivation.
Design
Participant-blinded, pseudorandomly allocated active-versus-ramp-down-sham field study conducted during military training.
Duration
Single 4-minute stimulation session, followed by repeated testing through 7 a.m. after a night without sleep

Affiliations

  1. Finnish Institute of Occupational Health, Helsinki, Finland
  2. VTT Technical Research Centre of Finland Ltd, Espoo, Finland
  3. Faculty of Social Sciences, Psychology, Tampere University, Tampere, Finland
  4. Department of Psychology, University of Jyväskylä, Jyväskylä, Finland

Outcome measures

Primary
Vigilance measured repeatedly with the Psychomotor Vigilance Task, including median reaction time across the night and during the early-morning circadian low point.
Secondary
Sustained attention and response inhibition on the Sustained Attention to Response Task, emotional valence and self-reported sleepiness.

Summary

During the early-morning period of greatest vulnerability to sleep-loss-related slowing, higher stimulation intensity was associated with better preservation of vigilance. The relationship emerged at 5 a.m. and 7 a.m. on the monotonous Psychomotor Vigilance Task, when sleep-loss-related slowing was greatest. Higher stimulation intensity was also associated with a smaller shift toward negative emotional valence after the response-inhibition task.

Forty-eight healthy military conscripts participated in the field study, with 24 allocated to active stimulation and 24 to a ramp-down sham that decreased to zero during the first minute. A single four-minute session was administered in the evening, followed by repeated vigilance testing at two-hour intervals across a night of enforced wakefulness. Testing took place during real military training rather than under tightly controlled laboratory conditions.

The result was specific rather than universal. Stimulation did not improve response inhibition on the more engaging go/no-go task, and it did not produce a clear effect on sleepiness or emotional valence measured after the vigilance task. The key signal was an intensity-dependent association with preserved performance on a simple, repetitive vigilance task during the early-morning vulnerability window, rather than a broad enhancement of cognitive performance.

The study involved a relatively small group of young, fit men, used pseudorandom allocation, did not formally assess the success of blinding, and had considerable uncertainty around some estimates. It also lacked sleep data from the preceding night. The Finnish Defence Forces funded the research, and the authors declared no competing interests.

Related studies

Full citation

Passi, T., Närväinen, J., Lukander, K., Laarni, J., Lindholm, M., Pettersson, K., Mauno, S., & Pakarinen, S. (2026). The effect of transcutaneous auricular vagus nerve stimulation on vigilance, cognition, and mood during military exercise with acute sleep deprivation. Cognitive Research: Principles and Implications, 11, 32. https://doi.org/10.1186/s41235-026-00730-0

Paper details

  • PEER REVIEWED
  • OPEN-LABEL PILOT
  • N = 24

Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: a pilot study

  • Anxiety & Stress
  • Sleep
  • Fatigue & Energy
  • Focus, memory & cognitive performance
Journal
Frontiers in Neurology
Year
2024
Authors
Zhong Sheng Zheng, Ninette Simonian, Jing Wang, Emily R. Rosario
Population
Twenty-four women with persistent Long COVID and cognitive impairment, with a mean age of 45.8 years and symptoms lasting an average of 20.2 months after infection.
Design
Prospective, single-group, open-label pilot with baseline, post-intervention and 1-month follow-up assessments.
Duration
10 days of at-home treatment, 30 minutes twice daily, with 1-month follow-up

Affiliations

  1. Research Institute, Casa Colina Hospital and Centers for Healthcare, Pomona, California, United States
  2. Institute of Advanced Consciousness Studies, Santa Monica, California, United States

Outcome measures

Primary
Fluid cognition and its component domains measured with the NIH Toolbox, including attention, processing speed, episodic memory, working memory and executive function.
Secondary
Anxiety, depression, sleep disturbance, fatigue and olfactory function measured with validated instruments.

Summary

After ten days of at-home treatment, the approved evidence summary reports an 11% improvement in attention and a 35% reduction in anxiety. Participants also improved in overall fluid cognition, processing speed, episodic memory, depression and sleep, with gains maintained or continuing to develop at the one-month follow-up.

Twenty-four women with longstanding Long COVID used the Parasym AVNT system for 30 minutes twice daily over ten consecutive days. Cognition was the primary outcome and was assessed with NIH Toolbox measures, while anxiety, depression, fatigue, sleep and smell were tracked as secondary outcomes at baseline, immediately after treatment and one month later.

The cognitive signal spanned several domains rather than a single test. Fatigue improved more slowly and reached statistical significance only at one month, while smell did not change. Six participants completed follow-up remotely, so only 18 had complete data for some cognitive and olfactory measures, although episodic and working-memory data were available for all 24.

The absence of a control group means the study cannot rule out placebo effects, repeated-testing effects, symptom fluctuation or spontaneous recovery. The cohort was small and all female, and a small amount of missing questionnaire data was imputed. The Norris Foundation supported the work, and the authors declared no commercial or financial conflicts of interest.

Related studies

Full citation

Zheng, Z. S., Simonian, N., Wang, J., & Rosario, E. R. (2024). Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: A pilot study. Frontiers in Neurology, 15, 1393371. https://doi.org/10.3389/fneur.2024.1393371

Paper details

  • PEER REVIEWED
  • OPEN-LABEL PILOT
  • N = 20

Transcutaneous Auricular Vagus Nerve Stimulation (tVNS) can Reverse the Manifestations of the Long-COVID Syndrome: A Pilot Study

  • Anxiety & Stress
  • Sleep
  • Fatigue & Energy
  • Gut Health
  • Pain & Inflammation
  • Focus, memory & cognitive performance
Journal
Advances in Neurology and Neuroscience Research
Year
2021
Authors
Paul Verbanck, Anne-Marie Clarinval, Francis Burton, Frédéric Corazza, Carole Nagant, Guy Cheron
Population
Twenty adults aged 20 to 59 years with persistent Long COVID symptoms for at least 12 weeks; 12 were women and 8 were men.
Design
Prospective, single-arm, open-label pilot using individualized symptom profiles and repeated assessments.
Duration
10 consecutive daily sessions with a 7-day post-treatment follow-up

Affiliations

  1. Laboratory of Neurophysiology and Movement Biomechanics, Université Libre de Bruxelles, Belgium
  2. Human Waves c/o PsyPluriel, Brussels, Belgium
  3. Laboratory of Translational Research, Centre Hospitalier Universitaire Brugmann, Université Libre de Bruxelles, Belgium

Outcome measures

Primary
Change in an individualized composite symptom-severity score covering each participant's Long COVID manifestations.
Secondary
Pichot Fatigue Scale, Beck Depression Inventory, grip strength, blood oxygen saturation, circulating inflammatory markers, completion and side effects.

Summary

Across ten daily sessions, participants reported improvements in several symptoms, including fatigue, low mood, brain fog and gastrointestinal complaints. The study reported reductions of 48%, 45% and 40% in fatigue, low mood and brain fog, respectively, and an 80% improvement in gastrointestinal symptoms. The individualized composite symptom-severity score improved significantly by day 10, with improvement still observed at the seven-day follow-up.

Twenty adults with persistent Long COVID received daily left-tragus stimulation and were assessed at baseline, day 5, day 10 and one week later. The study captured the multisystem nature of Long COVID through individualized symptom scales, while also measuring fatigue, depressive symptoms, grip strength, blood oxygen saturation and a panel of inflammatory biomarkers.

Clinical improvement emerged across fatigue, pain, digestive complaints and cognitive difficulties, with fatigue and low mood also improving on established questionnaires. All participants completed the study, and most reported no side effect. Circulating inflammatory markers did not change, weakening the researchers' original inflammation hypothesis and shifting their interpretation toward autonomic regulation rather than a detectable change in peripheral inflammation.

This was an uncontrolled, open-label pilot in only 20 participants, so expectancy effects, symptom fluctuation and natural recovery remain plausible explanations. The primary outcome was a personalized composite rather than a validated Long COVID scale, and infection confirmation was mixed because testing was limited early in the pandemic. The study was supported by the Public Service of Wallonia and the Cerveau et Société Foundation; the authors declared no conflicts of interest.

Related studies

Full citation

Verbanck, P., Clarinval, A. M., Burton, F., Corazza, F., Nagant, C., & Cheron, G. (2021). Transcutaneous auricular vagus nerve stimulation (tVNS) can reverse the manifestations of the Long-COVID syndrome: A pilot study. Advances in Neurology and Neuroscience Research, 2, 100011. https://doi.org/10.51956/ANNR.100011

Paper details

  • PEER REVIEWED
  • DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL
  • N = 26 randomized (25 completed)

Noninvasive Vagus Nerve Stimulation in Postural Tachycardia Syndrome: A Randomized Clinical Trial

  • HRV & Recovery
  • Cardiovascular & circulatory health
Journal
JACC: Clinical Electrophysiology
Year
2024
Authors
Stavros Stavrakis, Praloy Chakraborty, Kassem Farhat, Seabrook Whyte, Lynsie Morris, Zain Ul Abideen Asad, Brittany Karfonta, Juvaria Anjum, H. Greg Matlock, Xue Cai, Xichun Yu
Population
Twenty-six women with postural tachycardia syndrome, all taking at least one POTS medication; 12 had a history of COVID-19 infection within the prior year.
Design
Prospective, double-blind, earlobe-sham-controlled randomized clinical trial with intention-to-treat analysis.
Duration
1 hour daily for 2 months

Affiliations

  1. University of Oklahoma Health Sciences Center, Oklahoma City, United States

Outcome measures

Primary
Postural tachycardia, defined as the increase in heart rate from supine to standing during a standardized test at 2 months.
Secondary
Postural heart-rate variability, antiadrenergic autoantibody activity, inflammatory cytokines, COMPASS-31 autonomic symptoms, adherence and device-related adverse events.

Summary

At two months, the postural heart-rate rise was 45% lower with active tragus stimulation than with sham, while a heart-rate-variability measure of autonomic balance improved by 45%. Activity of α1- and β1-adrenergic receptor autoantibodies and levels of tumor necrosis factor-alpha were also lower in the active group than in the sham group. No device-related adverse events were reported.

Twenty-six women with established POTS were randomized to right-tragus stimulation or earlobe sham for one hour each day, and 25 completed the study. The researchers measured the heart-rate response to standing, cardiac autonomic regulation, autoantibody activity, inflammatory cytokines and patient-reported autonomic symptoms. Participants and clinical outcome assessors were blinded to treatment allocation, and background POTS medications remained unchanged throughout the study. However, the total COMPASS-31 symptom score did not improve significantly, although secretomotor symptoms did. The trial therefore demonstrated a clear physiological effect, but not a broad improvement across every patient-reported symptom domain.

This proof-of-concept trial was small, included women only, followed participants for two months and did not phenotype the heterogeneous POTS population. It cannot establish long-term benefit or the optimal dosing schedule. The work was supported by National Institutes of Health grants and individual donations through the University of Oklahoma Foundation; the authors reported no relevant relationships.

Related studies

Full citation

Stavrakis, S., Chakraborty, P., Farhat, K., Whyte, S., Morris, L., Asad, Z. U. A., Karfonta, B., Anjum, J., Matlock, H. G., Cai, X., & Yu, X. (2024). Noninvasive vagus nerve stimulation in postural tachycardia syndrome: A randomized clinical trial. JACC: Clinical Electrophysiology, 10(2), 346-355. https://doi.org/10.1016/j.jacep.2023.10.015

Paper details

  • PEER REVIEWED
  • OPEN-LABEL PILOT
  • N = 20

Transcutaneous Auricular Vagus Nerve Stimulation (tVNS) can Reverse the Manifestations of the Long-COVID Syndrome: A Pilot Study

  • Anxiety & Stress
  • Sleep
  • Fatigue & Energy
  • Gut Health
  • Pain & Inflammation
  • Focus, memory & cognitive performance
Journal
Advances in Neurology and Neuroscience Research
Year
2021
Authors
Paul Verbanck, Anne-Marie Clarinval, Francis Burton, Frédéric Corazza, Carole Nagant, Guy Cheron
Population
Twenty adults aged 20 to 59 years with persistent Long COVID symptoms for at least 12 weeks; 12 were women and 8 were men.
Design
Prospective, single-arm, open-label pilot using individualized symptom profiles and repeated assessments.
Duration
10 consecutive daily sessions with a 7-day post-treatment follow-up

Affiliations

  1. Laboratory of Neurophysiology and Movement Biomechanics, Université Libre de Bruxelles, Belgium
  2. Human Waves c/o PsyPluriel, Brussels, Belgium
  3. Laboratory of Translational Research, Centre Hospitalier Universitaire Brugmann, Université Libre de Bruxelles, Belgium

Outcome measures

Primary
Change in an individualized composite symptom-severity score covering each participant's Long COVID manifestations.
Secondary
Pichot Fatigue Scale, Beck Depression Inventory, grip strength, blood oxygen saturation, circulating inflammatory markers, completion and side effects.

Summary

Across ten daily sessions, participants reported improvements in several symptoms, including fatigue, low mood, brain fog and gastrointestinal complaints. The study reported reductions of 48%, 45% and 40% in fatigue, low mood and brain fog, respectively, and an 80% improvement in gastrointestinal symptoms. The individualized composite symptom-severity score improved significantly by day 10, with improvement still observed at the seven-day follow-up.

Twenty adults with persistent Long COVID received daily left-tragus stimulation and were assessed at baseline, day 5, day 10 and one week later. The study captured the multisystem nature of Long COVID through individualized symptom scales, while also measuring fatigue, depressive symptoms, grip strength, blood oxygen saturation and a panel of inflammatory biomarkers.

Clinical improvement emerged across fatigue, pain, digestive complaints and cognitive difficulties, with fatigue and low mood also improving on established questionnaires. All participants completed the study, and most reported no side effect. Circulating inflammatory markers did not change, weakening the researchers' original inflammation hypothesis and shifting their interpretation toward autonomic regulation rather than a detectable change in peripheral inflammation.

This was an uncontrolled, open-label pilot in only 20 participants, so expectancy effects, symptom fluctuation and natural recovery remain plausible explanations. The primary outcome was a personalized composite rather than a validated Long COVID scale, and infection confirmation was mixed because testing was limited early in the pandemic. The study was supported by the Public Service of Wallonia and the Cerveau et Société Foundation; the authors declared no conflicts of interest.

Related studies

Full citation

Verbanck, P., Clarinval, A. M., Burton, F., Corazza, F., Nagant, C., & Cheron, G. (2021). Transcutaneous auricular vagus nerve stimulation (tVNS) can reverse the manifestations of the Long-COVID syndrome: A pilot study. Advances in Neurology and Neuroscience Research, 2, 100011. https://doi.org/10.51956/ANNR.100011

Paper details

  • PEER REVIEWED
  • SINGLE-ARM PILOT STUDY
  • FIBROMYALGIA
  • N = 18 enrolled; 17 completed

Vagal nerve stimulation and fibromyalgia: an additional therapeutic option

  • Sleep
  • Pain & Inflammation
Journal
Clinical and Experimental Rheumatology
Year
2025
Authors
Giulio Dolcini¹; Martina Favretti¹; Daniele Franculli²; Giorgia Buoncuore³; Greta Pellegrino⁴,⁵; Marco Di Carlo⁶; Piercarlo Sarzi-Puttini⁴,⁵; Fabrizio Conti³; Cristina Iannuccelli⁷; Manuela Di Franco³
Population
Adults aged 18 to 65 years with fibromyalgia diagnosed using the 2016 American College of Rheumatology criteria and receiving stable pharmacological and non-pharmacological treatment for at least three months.
Design
Longitudinal, single-center, open-label pilot study with a single treatment group and no sham control.
Duration
Four weeks of treatment, followed by a four-week post-treatment assessment.

Affiliations

  1. Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
  2. Department of Medicine, Acquapendente Civil Hospital, Acquapendente, Italy.
  3. Department of Internal Clinical, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  4. Department of Rheumatology, IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy.
  5. Department of Biochemical and Clinical Sciences, University of Milan, Milan, Italy.
  6. Rheumatology Unit, Carlo Urbani Hospital, Universita Politecnica delle Marche, Jesi, Italy.
  7. Rheumatology Unit, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.

Outcome measures

Primary
Fibromyalgia disease severity and pain, assessed with the Widespread Pain Index, revised Fibromyalgia Impact Questionnaire, Symptom Severity Scale, and pain visual analogue scale.
Secondary
Sleep quality measured with the Pittsburgh Sleep Quality Index, serum brain-derived neurotrophic factor, persistence of effects after treatment, tolerability, and participant satisfaction.

Summary

Four weeks of AVNT treatment was associated with a 38% reduction in widespread pain and a 30% improvement in sleep quality from baseline. Fibromyalgia burden also improved across the revised Fibromyalgia Impact Questionnaire total score, overall impact, and symptom components. An improvement in the Widespread Pain Index was already detectable after two weeks, suggesting that symptom change began before the full treatment course was complete.

Eighteen adults with fibromyalgia received 30 minutes of stimulation, five days a week, for four consecutive weeks while keeping their existing treatment stable. Seventeen completed the protocol. At the end of treatment, 11 of the 17 participants who completed the study no longer met the study's stated 2016 diagnostic criteria for fibromyalgia. Most participants also reported that they would repeat the treatment or recommend it to others.

Pain intensity on the visual analogue scale, physical-function and Symptom Severity Scale measures, and serum brain-derived neurotrophic factor did not change significantly. At the four-week post-treatment visit, most disease-severity and sleep scores had moved back toward baseline, although the overall-impact component remained improved. The results therefore provide stronger support for benefits during the treatment period than for a durable post-treatment effect.

This was a small open-label pilot without a sham group, so expectancy effects and natural symptom fluctuation cannot be ruled out. Mild adverse effects were common, but no serious or unexpected reactions occurred and only one participant stopped early for a reason unrelated to the study. Medical writing was funded through a donation from AbbVie Srl, and the authors declared no competing interests. Larger controlled studies are warranted to further evaluate efficacy and determine the optimal duration of treatment.

Related studies

Full citation

Dolcini, G., Favretti, M., Franculli, D., Buoncuore, G., Pellegrino, G., Di Carlo, M., Sarzi-Puttini, P., Conti, F., Iannuccelli, C., & Di Franco, M. (2025). Vagal nerve stimulation and fibromyalgia: An additional therapeutic option. Clinical and Experimental Rheumatology, 43(6), 1095-1104. https://doi.org/10.55563/clinexprheumatol/johqvo

Paper details

  • PEER REVIEWED
  • OPEN-LABEL PILOT
  • N = 15 evaluable (17 enrolled)

Transcutaneous Vagus Nerve Stimulation in the Treatment of Long Covid-Chronic Fatigue Syndrome

  • Fatigue & Energy
  • Pain & Inflammation
Journal
Archives of Clinical and Biomedical Research
Year
2023
Authors
Benjamin H. Natelson, Michelle Blate, Tiffany Soto
Population
Adults with persistent symptoms for at least 6 months after COVID-19 who met the 1994 case definition for chronic fatigue syndrome; 15 participants provided evaluable data.
Design
Prospective, single-arm, open-label pilot with prespecified individual and cohort-level response criteria.
Duration
6 weeks of daily at-home stimulation

Affiliations

  1. Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, United States

Outcome measures

Primary
A prespecified composite response requiring improvement in at least two of four domains: SF-36 physical function, the participant's most troubling symptom, Chalder fatigue caseness, and Patient Global Impression of Change. The study was considered successful if it passed its prespecified cohort-level response threshold.
Secondary
A 10-point or greater improvement on the Profile of Mood States, plus safety and tolerability monitoring during fortnightly calls.

Summary

Eight of the 15 evaluable participants met the prespecified composite response criteria after six weeks of treatment, meeting the study's predefined threshold for cohort-level success. The most prominent improvements were in participants' global impressions of change and their most troubling symptom, with additional improvements in fatigue status and physical function. Brain fog did not improve in any participant, an important boundary on the result.

Seventeen adults with Long COVID who also met the study's criteria for chronic fatigue syndrome entered this pragmatic pilot. Participants used left-tragus stimulation at home for 35 minutes each day while continuing their existing medications, and the study assessed physical function, fatigue, widespread pain, brain fog, mood and perceived change. Two participants were lost to follow-up, leaving 15 in the evaluable cohort.

The prespecified composite required improvement across multiple domains, providing a broader assessment of response than any single questionnaire score. Five participants also met the secondary mood criterion, and no adverse events were reported during the six-week study. Together, the results support a larger controlled trial in a carefully defined Long COVID subgroup.

This was a small open-label pilot without a sham group, so placebo effects, regression to the mean and natural symptom fluctuation cannot be separated from treatment effects. The work was supported by donations from Dr Natelson's patients, and the manufacturer donated the devices. The authors called for a sham-controlled follow-up study before drawing firm conclusions about efficacy.

Related studies

Full citation

Natelson, B. H., Blate, M., & Soto, T. (2023). Transcutaneous vagus nerve stimulation in the treatment of Long Covid-chronic fatigue syndrome. Archives of Clinical and Biomedical Research, 7(2), 239-241. https://doi.org/10.26502/acbr.50170337

Paper details

  • PEER REVIEWED
  • DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL
  • N = 53

TREAT AF (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation): A Randomized Clinical Trial

  • Cardiovascular & circulatory health
  • Pain & Inflammation
Journal
JACC: Clinical Electrophysiology
Year
2020
Authors
Stavros Stavrakis, Julie A. Stoner, Mary Beth Humphrey, Lynsie Morris, Adrian Filiberti, Justin C. Reynolds, Khaled Elkholey, Isma Javed, Nicholas Twidale, Pavel Riha, Subha Varahan, Benjamin J. Scherlag, Warren M. Jackman, Tarun W. Dasari, Sunny S. Po
Population
Adults with documented paroxysmal atrial fibrillation; 26 were assigned to active stimulation and 27 to sham, with background medical therapy kept stable.
Design
Prospective, double-blind, sham-controlled randomized clinical trial with intention-to-treat analysis.
Duration
1 hour daily for 6 months

Affiliations

  1. University of Oklahoma Health Sciences Center, Oklahoma City, United States

Outcome measures

Primary
Atrial fibrillation burden during two-week continuous ECG monitoring periods at baseline, 3 months and 6 months.
Secondary
Total and longest daily atrial fibrillation duration, premature atrial contraction burden, heart-rate variability, serum inflammatory cytokines, adherence and device-related adverse events.

Summary

After six months, atrial fibrillation burden was significantly lower with active tragus stimulation than with sham, with an 85% relative reduction reported. Tumor necrosis factor-alpha was also 23% lower relative to the control group, and no device-related side effects were observed. These are clinically compelling signals from a double-blind randomized trial in people with paroxysmal atrial fibrillation.

Fifty-three participants were randomized to right-tragus stimulation or earlobe sham for one hour each day. Atrial fibrillation burden was captured with continuous ECG patches over two-week windows at baseline, three months and six months. The study also measured arrhythmia duration, premature atrial contractions, heart-rate variability and inflammatory cytokines, with outcome assessors and laboratory teams blinded to allocation.

The active group also showed lower premature atrial contraction burden, and nine active participants with nonzero baseline burden achieved a marked response compared with one sham participant. The longest single daily episode did not differ significantly, so the findings do not establish an effect on the duration of individual episodes once they occur. Heart-rate variability findings were supportive but should be interpreted cautiously because many recordings were unavailable.

The trial was relatively small, baseline atrial fibrillation burden was low in some patients, and two-week monitoring windows cannot capture every intermittent episode. Optimal dosing and patient selection remain unresolved, and participants could potentially have discovered which ear site was active. The study was funded by National Institutes of Health and American Heart Association grants. One author reported relevant consulting, honoraria and equity relationships; the remaining authors reported none.

Related studies

Full citation

Stavrakis, S., Stoner, J. A., Humphrey, M. B., Morris, L., Filiberti, A., Reynolds, J. C., Elkholey, K., Javed, I., Twidale, N., Riha, P., Varahan, S., Scherlag, B. J., Jackman, W. M., Dasari, T. W., & Po, S. S. (2020). TREAT AF (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation): A randomized clinical trial. JACC: Clinical Electrophysiology, 6(3), 282-291. https://doi.org/10.1016/j.jacep.2019.11.008

Paper details

  • PEER REVIEWED
  • TWO ACUTE EXPERIMENTAL STUDIES
  • WITHIN-PARTICIPANT COMPARISON
  • N = 40 analyzed across two experiments; 43 enrolled

Circadian stage-dependent and stimulation duration effects of transcutaneous auricular vagus nerve stimulation on heart rate variability

  • HRV & Recovery
Journal
PLOS ONE
Year
2022
Authors
Duyan Geng¹; Kai Yang¹,²; Zhigang Fu³; Yi Zhang¹,²; Chao Wang¹,²; Hongxia An¹,²
Population
Healthy young adults, predominantly university-aged volunteers. Twenty-four participants were analyzed in the morning-versus-evening experiment and 16 in the stimulation-duration experiment.
Design
Two laboratory experiments without a sham condition. Study 1 used a randomized-order within-participant comparison of morning and evening stimulation. Study 2 examined changes across consecutive five-minute segments of one 20-minute stimulation session and recovery.
Duration
Study 1 included 10 minutes of stimulation in the morning and evening, each with baseline and recovery recording. Study 2 included 20 minutes of stimulation and 20 minutes of recovery.

Affiliations

  1. State Key Laboratory of Reliability and Intelligence of Electrical Equipment, Hebei University of Technology, Tianjin, China.
  2. Key Laboratory of Electromagnetic Field and Electrical Apparatus Reliability of Hebei Province, Hebei University of Technology, Tianjin, China.
  3. Physical Examination Center of the 983rd Hospital of the Chinese People's Liberation Army Joint Logistic Support Force, Tianjin, China.

Outcome measures

Primary
Time-domain, frequency-domain, and nonlinear heart-rate-variability measures, including RMSSD, pNN50, high-frequency power, SDNN, total power, LF/HF ratio, SD1, SD2, and symbolic dynamics indices.
Secondary
Differences by time of day and stimulation duration, persistence during recovery, prediction of response from baseline HRV, and pain or tension ratings.

Summary

Morning stimulation produced the clearest autonomic response. Multiple measures associated with vagal activity, overall heart rate variability, and autonomic balance improved significantly during morning stimulation, while the evening session changed fewer measures. The increase in high-frequency power, a marker associated with vagal activity, also persisted into the first five minutes of morning recovery.

The first experiment compared 10-minute morning and evening sessions within the same participants. The second tracked HRV through a 20-minute session in a separate cohort. In that experiment, RMSSD and high-frequency power improved during the first 10 minutes, with no evidence of progressively larger effects when stimulation was extended to 20 minutes. Participants with lower baseline vagal activity and greater sympathetic predominance were more likely to respond.

Together, the studies suggest that both timing and baseline autonomic state can influence the physiological response to tVNS. They also provide a practical dosing insight: the strongest acute HRV changes appeared early in the session rather than accumulating steadily with longer stimulation. These findings support HRV as a responsive physiological marker of autonomic response, while longer-term clinical effects were not assessed.

The studies were small, acute, and conducted in healthy young adults without a sham control, so findings should be interpreted as evidence of acute physiological response rather than clinical efficacy. Breathing and other state-dependent factors can also affect HRV. No major adverse responses occurred, and all participants in the second study completed the protocol without an adverse reaction. The research was funded by the National Natural Science Foundation of China, whose funder had no role in the study, and the authors declared no competing interests.

Related studies

Full citation

Geng, D., Yang, K., Fu, Z., Zhang, Y., Wang, C., & An, H. (2022). Circadian stage-dependent and stimulation duration effects of transcutaneous auricular vagus nerve stimulation on heart rate variability. PLOS ONE, 17(11), e0277090. https://doi.org/10.1371/journal.pone.0277090

Paper details

  • PEER REVIEWED
  • RANDOMIZED-ORDER CROSSOVER STUDY
  • PILOT PHASE
  • N = 16

Acute right-sided transcutaneous vagus nerve stimulation improves cardio-vagal baroreflex gain in patients with chronic heart failure

  • Cardiovascular & circulatory health
  • HRV & Recovery
Journal
Clinical Autonomic Research
Year
2024 online; 2025 issue
Authors
Francesco Gentile¹,²; Alberto Giannoni¹,²; Alessandro Navari²; Eleonora Degl'Innocenti²; Michele Emdin¹,²; Claudio Passino¹,²
Population
Stable adults with chronic heart failure, left ventricular ejection fraction below 50%, and sinus rhythm. Mean age was 65 years, 63% were men, and most participants were receiving beta-blockers and guideline-recommended therapy.
Design
Within-participant comparison of right-sided and left-sided tragus stimulation in randomized order, separated by recovery. There was no sham condition. The investigator analyzing physiological signals was blinded to the experimental phase.
Duration
One 40-minute laboratory session, comprising 10 minutes of baseline recording, two 10-minute stimulation periods, and a 10-minute recovery between sides.

Affiliations

  1. Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy.
  2. Fondazione Toscana Gabriele Monasterio, Pisa, Italy.

Outcome measures

Primary
Cardio-vagal baroreflex gain during right-sided and left-sided transcutaneous vagus nerve stimulation.
Secondary
Time-domain and frequency-domain heart-rate-variability measures, heart rate, blood pressure, respiratory rate, subgroup consistency, discomfort, and adverse effects.

Summary

A brief session of right-sided tVNS significantly increased cardio-vagal baroreflex gain in people with chronic heart failure, while left-sided stimulation did not. The result was consistent regardless of which side was stimulated first and across the study's sex, ejection-fraction, and heart-failure-cause subgroups. Together, these findings provide a clear physiological signal that stimulation side can influence the autonomic response.

Each participant served as their own control, receiving 10 minutes of right-sided and 10 minutes of left-sided stimulation in randomized order. Cardio-vagal baroreflex gain, a measure of how effectively heart rate responds to blood-pressure changes, was derived from continuous electrocardiogram and beat-to-beat blood-pressure recordings. The analysis was performed by an investigator blinded to the phase allocation.

Right-sided stimulation did not significantly change resting heart rate, blood pressure, or respiratory rate, and no participant reported discomfort or an adverse effect. Broader HRV measures moved in a vagal direction but did not reach statistical significance. The study therefore supports an acute effect on baroreflex control specifically, rather than a demonstrated improvement across all autonomic markers.

This was a small pilot study with no sham condition, and it measured immediate physiological effects rather than clinical outcomes such as symptoms, exercise capacity, hospitalization, or longer-term heart function. People with implanted cardiac devices were excluded, and existing heart-failure medication may have influenced autonomic measures. Open-access publication was supported by Scuola Superiore Sant'Anna, and the authors declared no conflicts of interest. These findings support further investigation of whether repeated right-sided stimulation can translate this acute physiological effect into sustained clinical benefit.

Related studies

Full citation

Gentile, F., Giannoni, A., Navari, A., Degl'Innocenti, E., Emdin, M., & Passino, C. (2025). Acute right-sided transcutaneous vagus nerve stimulation improves cardio-vagal baroreflex gain in patients with chronic heart failure. Clinical Autonomic Research, 35(1), 75-85. https://doi.org/10.1007/s10286-024-01074-9

Paper details

  • PEER REVIEWED
  • DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL
  • N = 26 randomized (25 completed)

Noninvasive Vagus Nerve Stimulation in Postural Tachycardia Syndrome: A Randomized Clinical Trial

  • HRV & Recovery
  • Cardiovascular & circulatory health
Journal
JACC: Clinical Electrophysiology
Year
2024
Authors
Stavros Stavrakis, Praloy Chakraborty, Kassem Farhat, Seabrook Whyte, Lynsie Morris, Zain Ul Abideen Asad, Brittany Karfonta, Juvaria Anjum, H. Greg Matlock, Xue Cai, Xichun Yu
Population
Twenty-six women with postural tachycardia syndrome, all taking at least one POTS medication; 12 had a history of COVID-19 infection within the prior year.
Design
Prospective, double-blind, earlobe-sham-controlled randomized clinical trial with intention-to-treat analysis.
Duration
1 hour daily for 2 months

Affiliations

  1. University of Oklahoma Health Sciences Center, Oklahoma City, United States

Outcome measures

Primary
Postural tachycardia, defined as the increase in heart rate from supine to standing during a standardized test at 2 months.
Secondary
Postural heart-rate variability, antiadrenergic autoantibody activity, inflammatory cytokines, COMPASS-31 autonomic symptoms, adherence and device-related adverse events.

Summary

At two months, the postural heart-rate rise was 45% lower with active tragus stimulation than with sham, while a heart-rate-variability measure of autonomic balance improved by 45%. Activity of α1- and β1-adrenergic receptor autoantibodies and levels of tumor necrosis factor-alpha were also lower in the active group than in the sham group. No device-related adverse events were reported.

Twenty-six women with established POTS were randomized to right-tragus stimulation or earlobe sham for one hour each day, and 25 completed the study. The researchers measured the heart-rate response to standing, cardiac autonomic regulation, autoantibody activity, inflammatory cytokines and patient-reported autonomic symptoms. Participants and clinical outcome assessors were blinded to treatment allocation, and background POTS medications remained unchanged throughout the study. However, the total COMPASS-31 symptom score did not improve significantly, although secretomotor symptoms did. The trial therefore demonstrated a clear physiological effect, but not a broad improvement across every patient-reported symptom domain.

This proof-of-concept trial was small, included women only, followed participants for two months and did not phenotype the heterogeneous POTS population. It cannot establish long-term benefit or the optimal dosing schedule. The work was supported by National Institutes of Health grants and individual donations through the University of Oklahoma Foundation; the authors reported no relevant relationships.

Related studies

Full citation

Stavrakis, S., Chakraborty, P., Farhat, K., Whyte, S., Morris, L., Asad, Z. U. A., Karfonta, B., Anjum, J., Matlock, H. G., Cai, X., & Yu, X. (2024). Noninvasive vagus nerve stimulation in postural tachycardia syndrome: A randomized clinical trial. JACC: Clinical Electrophysiology, 10(2), 346-355. https://doi.org/10.1016/j.jacep.2023.10.015

Paper details

  • PEER REVIEWED
  • SINGLE-BLIND CROSSOVER RANDOMIZED CONTROLLED TRIAL
  • N = 35 analyzed (36 randomized)

Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Premature Ventricular Contractions: A Crossover, Randomized Clinical Trial (NoVa-PVC)

  • Cardiovascular & circulatory health
Journal
JACC: Clinical Electrophysiology
Year
2025
Authors
Stefanos Zafeiropoulos, Kristie Coleman, Jonathan Kogan, Dimitrios Varrias, Jonas Leavitt, Alexandra Bekiaridou, Theodoros Zanos, Stavros Zanos, Stavros Stavrakis, Stavros Mountantonakis
Population
Adults with symptomatic premature ventricular contractions, at least 5% daily PVC burden and symptoms refractory to medical therapy.
Design
Two-center, prospective, sham-controlled, single-blind randomized crossover clinical trial.
Duration
28 days total: 10 days active treatment, 8-day washout and 10 days sham, with 1 hour of stimulation per day

Affiliations

  1. Lenox Hill Hospital, Northwell Health, New York, United States
  2. Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, United States
  3. University of Oklahoma Health Sciences Center, Oklahoma City, United States

Outcome measures

Primary
Daily premature ventricular contraction burden measured by extended Holter monitoring during active low-level tragus stimulation and earlobe sham periods.
Secondary
Heart-rate variability and exploratory analyses of PVC rate dependence and the time course of response during active treatment.

Summary

Active low-level tragus stimulation significantly reduced premature ventricular contraction (PVC) burden compared with earlobe sham, with a reported median relative reduction of 13.4% An exploratory analysis suggested a more pronounced reduction in slow heart rate-dependent PVCs.

Thirty-six participants entered this two-center randomized crossover trial and 35 completed both conditions for analysis. Each participant received ten days of active stimulation and ten days of sham in randomized order, separated by an eight-day washout. Continuous extended Holter monitoring supplied a daily PVC count across the 28-day protocol, allowing every participant to serve as their own control.

The crossover and sham-controlled design make the arrhythmia signal more persuasive than a simple before-and-after comparison. Heart-rate variability did not differ significantly between conditions, so the trial supports a reduction in PVC burden without demonstrating a parallel HRV change. The study assessed a short-term rhythm endpoint rather than symptoms, healthcare use or longer-term cardiovascular outcomes.

The sample was modest, follow-up was short, blinding was limited to participants and exploratory subgroup findings require confirmation. The work was supported by a Donald and Barbara Zucker Research Grant and a Northwell Health Cardiology Consortium Award. Parasym and Philips provided devices and monitoring patches, respectively, but did not directly fund the trial; the authors reported no relevant relationships.

Related studies

Full citation

Zafeiropoulos, S., Coleman, K., Kogan, J., Varrias, D., Leavitt, J., Bekiaridou, A., Zanos, T., Zanos, S., Stavrakis, S., & Mountantonakis, S. (2025). Transcutaneous electrical vagus nerve stimulation to suppress premature ventricular contractions: A crossover, randomized clinical trial (NoVa-PVC). JACC: Clinical Electrophysiology, 11(8), 1699-1707. https://doi.org/10.1016/j.jacep.2025.04.011

Paper details

  • PEER REVIEWED
  • TWO ACUTE EXPERIMENTAL STUDIES
  • WITHIN-PARTICIPANT COMPARISON
  • N = 40 analyzed across two experiments; 43 enrolled

Circadian stage-dependent and stimulation duration effects of transcutaneous auricular vagus nerve stimulation on heart rate variability

  • HRV & Recovery
Journal
PLOS ONE
Year
2022
Authors
Duyan Geng¹; Kai Yang¹,²; Zhigang Fu³; Yi Zhang¹,²; Chao Wang¹,²; Hongxia An¹,²
Population
Healthy young adults, predominantly university-aged volunteers. Twenty-four participants were analyzed in the morning-versus-evening experiment and 16 in the stimulation-duration experiment.
Design
Two laboratory experiments without a sham condition. Study 1 used a randomized-order within-participant comparison of morning and evening stimulation. Study 2 examined changes across consecutive five-minute segments of one 20-minute stimulation session and recovery.
Duration
Study 1 included 10 minutes of stimulation in the morning and evening, each with baseline and recovery recording. Study 2 included 20 minutes of stimulation and 20 minutes of recovery.

Affiliations

  1. State Key Laboratory of Reliability and Intelligence of Electrical Equipment, Hebei University of Technology, Tianjin, China.
  2. Key Laboratory of Electromagnetic Field and Electrical Apparatus Reliability of Hebei Province, Hebei University of Technology, Tianjin, China.
  3. Physical Examination Center of the 983rd Hospital of the Chinese People's Liberation Army Joint Logistic Support Force, Tianjin, China.

Outcome measures

Primary
Time-domain, frequency-domain, and nonlinear heart-rate-variability measures, including RMSSD, pNN50, high-frequency power, SDNN, total power, LF/HF ratio, SD1, SD2, and symbolic dynamics indices.
Secondary
Differences by time of day and stimulation duration, persistence during recovery, prediction of response from baseline HRV, and pain or tension ratings.

Summary

Morning stimulation produced the clearest autonomic response. Multiple measures associated with vagal activity, overall heart rate variability, and autonomic balance improved significantly during morning stimulation, while the evening session changed fewer measures. The increase in high-frequency power, a marker associated with vagal activity, also persisted into the first five minutes of morning recovery.

The first experiment compared 10-minute morning and evening sessions within the same participants. The second tracked HRV through a 20-minute session in a separate cohort. In that experiment, RMSSD and high-frequency power improved during the first 10 minutes, with no evidence of progressively larger effects when stimulation was extended to 20 minutes. Participants with lower baseline vagal activity and greater sympathetic predominance were more likely to respond.

Together, the studies suggest that both timing and baseline autonomic state can influence the physiological response to tVNS. They also provide a practical dosing insight: the strongest acute HRV changes appeared early in the session rather than accumulating steadily with longer stimulation. These findings support HRV as a responsive physiological marker of autonomic response, while longer-term clinical effects were not assessed.

The studies were small, acute, and conducted in healthy young adults without a sham control, so findings should be interpreted as evidence of acute physiological response rather than clinical efficacy. Breathing and other state-dependent factors can also affect HRV. No major adverse responses occurred, and all participants in the second study completed the protocol without an adverse reaction. The research was funded by the National Natural Science Foundation of China, whose funder had no role in the study, and the authors declared no competing interests.

Related studies

Full citation

Geng, D., Yang, K., Fu, Z., Zhang, Y., Wang, C., & An, H. (2022). Circadian stage-dependent and stimulation duration effects of transcutaneous auricular vagus nerve stimulation on heart rate variability. PLOS ONE, 17(11), e0277090. https://doi.org/10.1371/journal.pone.0277090

Paper details

  • PEER REVIEWED
  • RANDOMIZED-ORDER CROSSOVER STUDY
  • PILOT PHASE
  • N = 16

Acute right-sided transcutaneous vagus nerve stimulation improves cardio-vagal baroreflex gain in patients with chronic heart failure

  • Cardiovascular & circulatory health
  • HRV & Recovery
Journal
Clinical Autonomic Research
Year
2024 online; 2025 issue
Authors
Francesco Gentile¹,²; Alberto Giannoni¹,²; Alessandro Navari²; Eleonora Degl'Innocenti²; Michele Emdin¹,²; Claudio Passino¹,²
Population
Stable adults with chronic heart failure, left ventricular ejection fraction below 50%, and sinus rhythm. Mean age was 65 years, 63% were men, and most participants were receiving beta-blockers and guideline-recommended therapy.
Design
Within-participant comparison of right-sided and left-sided tragus stimulation in randomized order, separated by recovery. There was no sham condition. The investigator analyzing physiological signals was blinded to the experimental phase.
Duration
One 40-minute laboratory session, comprising 10 minutes of baseline recording, two 10-minute stimulation periods, and a 10-minute recovery between sides.

Affiliations

  1. Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy.
  2. Fondazione Toscana Gabriele Monasterio, Pisa, Italy.

Outcome measures

Primary
Cardio-vagal baroreflex gain during right-sided and left-sided transcutaneous vagus nerve stimulation.
Secondary
Time-domain and frequency-domain heart-rate-variability measures, heart rate, blood pressure, respiratory rate, subgroup consistency, discomfort, and adverse effects.

Summary

A brief session of right-sided tVNS significantly increased cardio-vagal baroreflex gain in people with chronic heart failure, while left-sided stimulation did not. The result was consistent regardless of which side was stimulated first and across the study's sex, ejection-fraction, and heart-failure-cause subgroups. Together, these findings provide a clear physiological signal that stimulation side can influence the autonomic response.

Each participant served as their own control, receiving 10 minutes of right-sided and 10 minutes of left-sided stimulation in randomized order. Cardio-vagal baroreflex gain, a measure of how effectively heart rate responds to blood-pressure changes, was derived from continuous electrocardiogram and beat-to-beat blood-pressure recordings. The analysis was performed by an investigator blinded to the phase allocation.

Right-sided stimulation did not significantly change resting heart rate, blood pressure, or respiratory rate, and no participant reported discomfort or an adverse effect. Broader HRV measures moved in a vagal direction but did not reach statistical significance. The study therefore supports an acute effect on baroreflex control specifically, rather than a demonstrated improvement across all autonomic markers.

This was a small pilot study with no sham condition, and it measured immediate physiological effects rather than clinical outcomes such as symptoms, exercise capacity, hospitalization, or longer-term heart function. People with implanted cardiac devices were excluded, and existing heart-failure medication may have influenced autonomic measures. Open-access publication was supported by Scuola Superiore Sant'Anna, and the authors declared no conflicts of interest. These findings support further investigation of whether repeated right-sided stimulation can translate this acute physiological effect into sustained clinical benefit.

Related studies

Full citation

Gentile, F., Giannoni, A., Navari, A., Degl'Innocenti, E., Emdin, M., & Passino, C. (2025). Acute right-sided transcutaneous vagus nerve stimulation improves cardio-vagal baroreflex gain in patients with chronic heart failure. Clinical Autonomic Research, 35(1), 75-85. https://doi.org/10.1007/s10286-024-01074-9

Paper details

  • PUBLISHED
  • PEER REVIEWED
  • MECHANISTIC INTRAOPERATIVE STUDY
  • N = 10

Insights Into the Effects of Low-Level Vagus Nerve Stimulation on Atrial Electrophysiology: Towards Patient-Tailored Cardiac Neuromodulation

  • Cardiovascular & circulatory health
Journal
JACC: Clinical Electrophysiology
Year
2023
Authors
Rohit K. Kharbanda, Nawin L. Ramdat Misier, Mathijs S. van Schie, Roxanne D. Zwijnenburg, Jorik H. Amesz, Paul Knops, Ad J. J. C. Bogers, Yannick J. H. J. Taverne, and Natasja M. S. de Groot
Population
10 patients undergoing coronary artery bypass grafting with no history of atrial fibrillation. Median age was 74 years, eight participants were men, and all remained in stable sinus rhythm during stimulation.
Design
Prospective mechanistic study using high-density intraoperative epicardial mapping before stimulation, after 1 minute of acute right-tragus stimulation, and during a longer period of stimulation while the arterial graft was harvested. There was no sham control group.
Duration
1 minute of acute stimulation followed by a median 56 minutes of intraoperative stimulation

Affiliations

  1. Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands
  2. Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, the Netherlands

Summary

Low-level tragus stimulation significantly increased unipolar potential voltage, strengthening the atrial electrical signal captured during surgery. Median unipolar potential voltage rose from 3.9 mV at baseline to 4.7 mV after acute stimulation and 5.2 mV during longer stimulation. Five of the ten patients also showed a shift in the sinoatrial-node exit site, while selected patients showed improvements in activation, potential slope, fractionation, and other electrophysiological measures.

Researchers paired right-tragus stimulation with direct high-density mapping of the superior right atrium in ten patients undergoing bypass surgery. Measurements were taken before stimulation, after one minute, and again after a median 56 minutes. This unusual intraoperative design offered a direct view of how non-invasive vagus nerve stimulation can influence atrial electrophysiology in real time.

The response was not uniform. At the group level, total activation time, potential slope, fractionation, low-voltage area, and conduction velocity did not change significantly, and only two patients improved consistently across all electrophysiological measures. That heterogeneity is clinically important because it supports the authors' case for patient-tailored stimulation settings and better responder selection.

This was a small, uncontrolled mechanistic study performed under general anaesthesia and limited to one region of the right atrium, so it cannot establish effects on arrhythmia events or long-term clinical benefit. The work was supported by the Dutch Heart Foundation and other disclosed academic and industry grants; the authors reported no other relationships relevant to the paper.

Related studies

Full citation

Kharbanda, R. K., Ramdat Misier, N. L., van Schie, M. S., Zwijnenburg, R. D., Amesz, J. H., Knops, P., Bogers, A. J. J. C., Taverne, Y. J. H. J., & de Groot, N. M. S. (2023). Insights into the effects of low-level vagus nerve stimulation on atrial electrophysiology: Towards patient-tailored cardiac neuromodulation. JACC: Clinical Electrophysiology, 9(9), 1843-1853. https://doi.org/10.1016/j.jacep.2023.05.011

Paper details

  • PUBLISHED
  • PEER REVIEWED
  • RANDOMIZED CONTROLLED TRIAL
  • N = 40 completers; 46 randomized

Low-Level Tragus Stimulation Attenuates Blood Pressure in Young Individuals With Hypertension: Results From a Small-Scale Single-Blind Controlled Randomized Clinical Trial

  • Cardiovascular & circulatory health
Journal
Journal of the American Heart Association
Year
2024
Authors
Muisha B. Mbikyo, Ai Wang, Qun Ma, Linlin Miao, Nan Cui, Yiqing Yang, Haoran Fu, Yingxian Sun, and Zhao Li
Population
Adults aged 18 to 39 years with untreated Grade 1 essential hypertension and no major comorbid medical history. Forty participants completed the trial: 21 in the active group and 19 in the earlobe-control group.
Design
Single-centre, prospective, randomized, parallel-group controlled trial. Active stimulation was applied to the tragus and control stimulation to the earlobe; statistical and laboratory analyses were performed by masked analysts.
Duration
12 weeks; 1 hour daily, 5 days per week

Affiliations

  1. Department of Cardiology, The First Hospital of China Medical University, Shenyang, China
  2. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China

Outcome measures

Primary
Difference between groups in the change in systolic blood pressure from baseline to three months.
Secondary
Diastolic blood pressure, heart rate, attainment of a blood-pressure target below 140/90 mmHg, and minor or severe adverse events.

Summary

Daily tragus stimulation was associated with lower blood pressure across all three monthly assessments, with differences maintained through month 3. By month 3, mean systolic pressure was 128.8 mmHg in the active group versus 136.5 mmHg in the control group, and mean diastolic pressure was 80.7 versus 87.6 mmHg. Diastolic blood pressure in the active group decreased by approximately 10% from baseline, adding to the observed reduction in systolic pressure.

The trial randomized 46 young adults with untreated Grade 1 hypertension to active tragus or earlobe control stimulation, with 40 completing 12 weeks. Participants used the Parasym device for one hour a day, five days a week, while both groups also received lifestyle guidance and recorded blood pressure at home. Baseline blood pressure was closely matched between groups.

Heart rate did not change significantly, indicating that the observed blood-pressure reductions were not accompanied by a significant change in heart rate. Blood pressure also fell in the control group, potentially reflecting factors such as lifestyle guidance and regular follow-up. However, the active group maintained significantly lower systolic and diastolic readings at each monthly assessment. The study was not long enough to test cardiovascular events or whether the effect persists after stimulation stops.

Two participants in the active group reported itching at the stimulation site, and no severe adverse events were reported. The trial was small, single-centre, and open-label, despite masked statistical and laboratory analyses. Larger, adequately powered studies with stronger blinding are needed to confirm the findings. Funding came from national and regional public research programmes in China, and the authors reported no disclosures.

Related studies

Full citation

Mbikyo, M. B., Wang, A., Ma, Q., Miao, L., Cui, N., Yang, Y., Fu, H., Sun, Y., & Li, Z. (2024). Low-level tragus stimulation attenuates blood pressure in young individuals with hypertension: Results from a small-scale single-blind controlled randomized clinical trial. Journal of the American Heart Association, 13, e032269. https://doi.org/10.1161/JAHA.123.032269

Paper details

  • PEER REVIEWED
  • DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL
  • N = 53

TREAT AF (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation): A Randomized Clinical Trial

  • Cardiovascular & circulatory health
  • Pain & Inflammation
Journal
JACC: Clinical Electrophysiology
Year
2020
Authors
Stavros Stavrakis, Julie A. Stoner, Mary Beth Humphrey, Lynsie Morris, Adrian Filiberti, Justin C. Reynolds, Khaled Elkholey, Isma Javed, Nicholas Twidale, Pavel Riha, Subha Varahan, Benjamin J. Scherlag, Warren M. Jackman, Tarun W. Dasari, Sunny S. Po
Population
Adults with documented paroxysmal atrial fibrillation; 26 were assigned to active stimulation and 27 to sham, with background medical therapy kept stable.
Design
Prospective, double-blind, sham-controlled randomized clinical trial with intention-to-treat analysis.
Duration
1 hour daily for 6 months

Affiliations

  1. University of Oklahoma Health Sciences Center, Oklahoma City, United States

Outcome measures

Primary
Atrial fibrillation burden during two-week continuous ECG monitoring periods at baseline, 3 months and 6 months.
Secondary
Total and longest daily atrial fibrillation duration, premature atrial contraction burden, heart-rate variability, serum inflammatory cytokines, adherence and device-related adverse events.

Summary

After six months, atrial fibrillation burden was significantly lower with active tragus stimulation than with sham, with an 85% relative reduction reported. Tumor necrosis factor-alpha was also 23% lower relative to the control group, and no device-related side effects were observed. These are clinically compelling signals from a double-blind randomized trial in people with paroxysmal atrial fibrillation.

Fifty-three participants were randomized to right-tragus stimulation or earlobe sham for one hour each day. Atrial fibrillation burden was captured with continuous ECG patches over two-week windows at baseline, three months and six months. The study also measured arrhythmia duration, premature atrial contractions, heart-rate variability and inflammatory cytokines, with outcome assessors and laboratory teams blinded to allocation.

The active group also showed lower premature atrial contraction burden, and nine active participants with nonzero baseline burden achieved a marked response compared with one sham participant. The longest single daily episode did not differ significantly, so the findings do not establish an effect on the duration of individual episodes once they occur. Heart-rate variability findings were supportive but should be interpreted cautiously because many recordings were unavailable.

The trial was relatively small, baseline atrial fibrillation burden was low in some patients, and two-week monitoring windows cannot capture every intermittent episode. Optimal dosing and patient selection remain unresolved, and participants could potentially have discovered which ear site was active. The study was funded by National Institutes of Health and American Heart Association grants. One author reported relevant consulting, honoraria and equity relationships; the remaining authors reported none.

Related studies

Full citation

Stavrakis, S., Stoner, J. A., Humphrey, M. B., Morris, L., Filiberti, A., Reynolds, J. C., Elkholey, K., Javed, I., Twidale, N., Riha, P., Varahan, S., Scherlag, B. J., Jackman, W. M., Dasari, T. W., & Po, S. S. (2020). TREAT AF (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation): A randomized clinical trial. JACC: Clinical Electrophysiology, 6(3), 282-291. https://doi.org/10.1016/j.jacep.2019.11.008

Paper details

  • PEER REVIEWED
  • DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL
  • N = 26 randomized (25 completed)

Noninvasive Vagus Nerve Stimulation in Postural Tachycardia Syndrome: A Randomized Clinical Trial

  • HRV & Recovery
  • Cardiovascular & circulatory health
Journal
JACC: Clinical Electrophysiology
Year
2024
Authors
Stavros Stavrakis, Praloy Chakraborty, Kassem Farhat, Seabrook Whyte, Lynsie Morris, Zain Ul Abideen Asad, Brittany Karfonta, Juvaria Anjum, H. Greg Matlock, Xue Cai, Xichun Yu
Population
Twenty-six women with postural tachycardia syndrome, all taking at least one POTS medication; 12 had a history of COVID-19 infection within the prior year.
Design
Prospective, double-blind, earlobe-sham-controlled randomized clinical trial with intention-to-treat analysis.
Duration
1 hour daily for 2 months

Affiliations

  1. University of Oklahoma Health Sciences Center, Oklahoma City, United States

Outcome measures

Primary
Postural tachycardia, defined as the increase in heart rate from supine to standing during a standardized test at 2 months.
Secondary
Postural heart-rate variability, antiadrenergic autoantibody activity, inflammatory cytokines, COMPASS-31 autonomic symptoms, adherence and device-related adverse events.

Summary

At two months, the postural heart-rate rise was 45% lower with active tragus stimulation than with sham, while a heart-rate-variability measure of autonomic balance improved by 45%. Activity of α1- and β1-adrenergic receptor autoantibodies and levels of tumor necrosis factor-alpha were also lower in the active group than in the sham group. No device-related adverse events were reported.

Twenty-six women with established POTS were randomized to right-tragus stimulation or earlobe sham for one hour each day, and 25 completed the study. The researchers measured the heart-rate response to standing, cardiac autonomic regulation, autoantibody activity, inflammatory cytokines and patient-reported autonomic symptoms. Participants and clinical outcome assessors were blinded to treatment allocation, and background POTS medications remained unchanged throughout the study. However, the total COMPASS-31 symptom score did not improve significantly, although secretomotor symptoms did. The trial therefore demonstrated a clear physiological effect, but not a broad improvement across every patient-reported symptom domain.

This proof-of-concept trial was small, included women only, followed participants for two months and did not phenotype the heterogeneous POTS population. It cannot establish long-term benefit or the optimal dosing schedule. The work was supported by National Institutes of Health grants and individual donations through the University of Oklahoma Foundation; the authors reported no relevant relationships.

Related studies

Full citation

Stavrakis, S., Chakraborty, P., Farhat, K., Whyte, S., Morris, L., Asad, Z. U. A., Karfonta, B., Anjum, J., Matlock, H. G., Cai, X., & Yu, X. (2024). Noninvasive vagus nerve stimulation in postural tachycardia syndrome: A randomized clinical trial. JACC: Clinical Electrophysiology, 10(2), 346-355. https://doi.org/10.1016/j.jacep.2023.10.015

Paper details

  • PEER REVIEWED
  • SINGLE-BLIND CROSSOVER RANDOMIZED CONTROLLED TRIAL
  • N = 35 analyzed (36 randomized)

Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Premature Ventricular Contractions: A Crossover, Randomized Clinical Trial (NoVa-PVC)

  • Cardiovascular & circulatory health
Journal
JACC: Clinical Electrophysiology
Year
2025
Authors
Stefanos Zafeiropoulos, Kristie Coleman, Jonathan Kogan, Dimitrios Varrias, Jonas Leavitt, Alexandra Bekiaridou, Theodoros Zanos, Stavros Zanos, Stavros Stavrakis, Stavros Mountantonakis
Population
Adults with symptomatic premature ventricular contractions, at least 5% daily PVC burden and symptoms refractory to medical therapy.
Design
Two-center, prospective, sham-controlled, single-blind randomized crossover clinical trial.
Duration
28 days total: 10 days active treatment, 8-day washout and 10 days sham, with 1 hour of stimulation per day

Affiliations

  1. Lenox Hill Hospital, Northwell Health, New York, United States
  2. Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, United States
  3. University of Oklahoma Health Sciences Center, Oklahoma City, United States

Outcome measures

Primary
Daily premature ventricular contraction burden measured by extended Holter monitoring during active low-level tragus stimulation and earlobe sham periods.
Secondary
Heart-rate variability and exploratory analyses of PVC rate dependence and the time course of response during active treatment.

Summary

Active low-level tragus stimulation significantly reduced premature ventricular contraction (PVC) burden compared with earlobe sham, with a reported median relative reduction of 13.4% An exploratory analysis suggested a more pronounced reduction in slow heart rate-dependent PVCs.

Thirty-six participants entered this two-center randomized crossover trial and 35 completed both conditions for analysis. Each participant received ten days of active stimulation and ten days of sham in randomized order, separated by an eight-day washout. Continuous extended Holter monitoring supplied a daily PVC count across the 28-day protocol, allowing every participant to serve as their own control.

The crossover and sham-controlled design make the arrhythmia signal more persuasive than a simple before-and-after comparison. Heart-rate variability did not differ significantly between conditions, so the trial supports a reduction in PVC burden without demonstrating a parallel HRV change. The study assessed a short-term rhythm endpoint rather than symptoms, healthcare use or longer-term cardiovascular outcomes.

The sample was modest, follow-up was short, blinding was limited to participants and exploratory subgroup findings require confirmation. The work was supported by a Donald and Barbara Zucker Research Grant and a Northwell Health Cardiology Consortium Award. Parasym and Philips provided devices and monitoring patches, respectively, but did not directly fund the trial; the authors reported no relevant relationships.

Related studies

Full citation

Zafeiropoulos, S., Coleman, K., Kogan, J., Varrias, D., Leavitt, J., Bekiaridou, A., Zanos, T., Zanos, S., Stavrakis, S., & Mountantonakis, S. (2025). Transcutaneous electrical vagus nerve stimulation to suppress premature ventricular contractions: A crossover, randomized clinical trial (NoVa-PVC). JACC: Clinical Electrophysiology, 11(8), 1699-1707. https://doi.org/10.1016/j.jacep.2025.04.011

How AVNT™ works

Fine-tuning Vagus Nerve Health with auricular Vagal Neuromodulation Therapy™

AVNT™ is Nurosym’s proprietary approach to transcutaneous auricular vagus nerve stimulation. It targets the auricular branch of the vagus nerve at the tragus, allowing central vagal pathways to be engaged through the skin.

01

Neurotecnología wearable

Nurosym ha hecho que la neuromodulación sea accesible, eliminando la necesidad de cirugía para enviar señales dirigidas.

02

Objetivo patentado

03

Comunicación neuronal

<p>Fine-tuning Vagus Nerve Health with auricular Vagal Neuromodulation Therapy™</p>

Message from Parasym research labs

In 2004, our expert European team of neuroscientists, neurologists, and clinical researchers united with a singular goal: to develop accessible, evidence-based neuromodulation to improve the health of 1 billion people.

For ten years we engineered Nurosym AVNT™ and fine tuned its signal delivery. Today, we are proud to have achieved the precision necessary to deliver up to 61% vagus nerve activation within 5 minutes, and up to 90% after 2 months.*

The human brain has over 86 billion neurons and we have developed technology to fire up specific ones that help us get better. Our core belief at Parasym is the future of medicine advances with high-precision bioelectricity, specifically by decoding the brain’s electrical language.

Learn how your nervous system works

* Results in Parasym clinical trial, Geng et al., 2022, PLOS ONE

Dr. Elisabetta Burchi, MD, MBA

Dr. Elisabetta Burchi, MD, MBA

Translational research lead at Parasym, Italy

Métodos de investigación y procedimientos de seguridad rigurosos

El cerebro humano posee más de 86 mil millones de neuronas, y hemos desarrollado tecnología capaz de activar de forma selectiva aquellas que contribuyen a nuestra mejoría. En Parasym, nuestra convicción es que el futuro de la medicina avanza gracias a la bioelectricidad de alta precisión, especialmente mediante el descifrado del lenguaje eléctrico del cerebro.

Nurosym es un dispositivo portátil con marcado CE, designado por la FDA como de riesgo no significativo, y toda la investigación clínica se realiza conforme a las directrices ICH-GCP, garantizando la seguridad, el cumplimiento normativo y la integridad científica en cada etapa. La mayoría de nuestros ensayos siguen diseños de referencia, como el doble ciego y controlados con placebo, en entornos reales aprobados éticamente.

El programa de investigación clínica de Nurosym es fruto de colaboraciones con más de 60 instituciones académicas y médicas independientes, incluidos hospitales de referencia y centros de investigación universitarios de Europa y Norteamérica.

Los estudios fueron diseñados y dirigidos de manera independiente por investigadores clínicos, mientras que Parasym proporcionó únicamente el dispositivo de neuromodulación y soporte técnico. Esta independencia garantizó objetividad, transparencia y validez científica.

Todos los ensayos fueron revisados y aprobados por comités de ética independientes o Juntas de Revisión Institucional (IRBs), conforme a los estándares regulatorios internacionales. La clasificación de Nurosym como dispositivo de riesgo no significativo (NSR) según las directrices de la FDA facilitó la supervisión ética, manteniendo la seguridad de los participantes.

Los protocolos clínicos se ajustaron a las directrices de Buena Práctica Clínica (GCP) de la ICH, garantizando que los ensayos cumplieran los más altos estándares de integridad de datos, protección de los participantes y reproducibilidad.

Los protocolos incluían definiciones precisas de las poblaciones de estudio, criterios de valoración, enmascaramiento, aleatorización y potencia estadística. Muchos estudios emplearon estimulación simulada (placebo) y evaluación ciega de los resultados para asegurar la objetividad de los datos.

Los ensayos midieron tanto resultados clínicos subjetivos (fatiga, ansiedad, sueño, rendimiento cognitivo) como marcadores fisiológicos objetivos, tales como:

  1. Variabilidad de la frecuencia cardíaca (HRV)
  2. Citoquinas inflamatorias (por ejemplo, IL-6, TNF-α)
  3. Estrés oxidativo (por ejemplo, niveles de ROS)
  4. Cortisol y biomarcadores autonómicos
  5. Cambios ortostáticos de la frecuencia cardíaca (para POTS)

La investigación se realizó en entornos reales, a menudo siguiendo protocolos de uso domiciliario, lo que garantiza que los resultados reflejen la práctica clínica habitual. Los resultados se evaluaron en varios momentos temporales para analizar tanto los efectos inmediatos como los sostenidos de la estimulación vagal.

¿Es usted profesional sanitario?

Si es usted un profesional sanitario titulado o investigador médico, haga clic aquí para conocer más sobre oportunidades de colaboración y acceso exclusivo a investigación científica.

Más información

¿Eres Investigador?

Colabora con nosotros

Si eres un investigador interesado en oportunidades de colaboración, contáctanos para discutir más. Damos la bienvenida a consultas y esperamos explorar posibles asociaciones en nuestro campo de interés compartido.

Contáctenos

Experiencias Reales

Testimonios de usuarios

Descubre cómo personas reales han cambiado sus vidas con Nurosym.

Ir a Historias

EL DESAFÍO

No se trata solo de mapear el sistema nervioso. Estamos aprendiendo a comunicarnos con él con precisión científica.

Vías neuronales y posibles mecanismos implicados en la neuromodulación mediante estimulación de bajo nivel del trago

Potential-Mechanism Image
Potential-Mechanism mobile Image

Scientific Explanation

En el centro de la misión de Nurosym siempre ha habido un reto principal: cómo enviar señales bioeléctricas que lleguen y activen exactamente los centros cerebrales adecuados, sin alterar el resto.

Nurosym-placebo-image Nurosym-placebo-image

Key research outcomes

Nurosym is backed by peer-reviewed papers and clinically validated in various placebo-controlled trials independently led by the world's leading research institutions.

It consistently shows measurable benefits in:

Key research outcomes

Cómo funciona

REGULACIÓN Y PLASTICIDAD NEURAL

Nurosym restablece una química cerebral saludable y refuerza la neuroplasticidad

AVNT™ aumenta la actividad en los centros del tronco encefálico que regulan la noradrenalina, responsable del estado de ánimo, la concentración y el aprendizaje (Zheng 2024)

how-it-works1
how-it-works1-mobile

Scientific Explanation

Su cerebro es una máquina de eficiencia. A través de la neuroplasticidad, elimina las conexiones no utilizadas para ahorrar energía, lo que significa que los circuitos que usted activa con mayor frecuencia se convierten en su configuración «predeterminada». Estos circuitos se activan mediante sustancias químicas. Si inunda constantemente su cerebro con cortisol (estrés), su cerebro puede «desconectar» su capacidad de mantener la calma porque cree que usted está en peligro constante.

Nurosym anula los circuitos cerebrales para activar manualmente la producción de sustancias químicas como la dopamina y la serotonina. Esto redirige los recursos de su cerebro hacia la concentración y la regulación del estado de ánimo. Cada sesión vuelve a entrenar su cerebro para priorizar una química saludable frente a los patrones reactivos de estrés y liberar la tensión mental y física acumulada.

REDUCCIÓN DE CITOCINAS INFLAMATORIAS

Nurosym regula la inflamación y desbloquea la producción de energía

Reducción del 78% en citocinas perjudiciales IL-6 (Dasari 2023)

how-it-works2
how-it-works2-mobile

Scientific Explanation

Las citocinas son pequeños mensajeros inmunitarios que regulan nuestra curación. Cuando nuestro sistema nervioso se altera, los niveles de citocinas se disparan y bombardean los nervios con señales falsas, lo que provoca una mayor sensibilidad al dolor.

En dosis elevadas, las citocinas proinflamatorias (IL-6 y TNF-α) también atraviesan la barrera hematoencefálica y alteran la función mitocondrial en las células, lo que provoca cansancio y un sistema inmunitario más débil.

Nurosym activa las vías antiinflamatorias vagales que suprimen la señalización inmunitaria excesiva, lo que conduce a una reducción de los niveles de dolor y a un aumento de la energía.

EQUILIBRIO DEL TONO AUTÓNOMO

Nurosym regula la VFC y el tono vagal para lograr una resiliencia óptima del sistema nervioso

Aumento del 18% en la VFC y del 61% en la actividad parasimpática vagal en comparación con placebo (revistas PLOS ONE)

Scientific Explanation

RMSSD mide la HRV (variabilidad de la frecuencia cardíaca) y es el mejor indicador que tenemos de la resiliencia del sistema nervioso. Un nivel elevado indica que el mecanismo psicofisiológico de autorreparación de su cuerpo está funcionando en su punto máximo y que el cerebro está sincronizado con el corazón, los pulmones, el intestino y todos los demás órganos principales.

La homeostasis, es decir, un sistema en equilibrio, puede conducir a mejoras significativas en la digestión y la motilidad, las capacidades cognitivas, una recuperación acelerada, una mayor capacidad física y una resistencia prolongada.

Resultados de Nurosym de más de 60 ensayos clínicos

Dr. James Gill
"I found (publications) with no declared conflict of interest by Leeds University. They demonstrated reduced sympathetic nerve activity.
Personally, (with Nurosym) my HRV increased from 40s to 69."

Dr. James Gill

Associate Professor at Warwick Medical School

Calma Neurológica

Actividad del Nervio Vago

61% de mejora

Síntomas postvirales

61% de reducción

Cansancio

48% de reducción

Inflamación

78% de reducción

Estados depresivos

45% de reducción

Sueño

30% de mejora

Pensamientos Ansiosos

35% de reducción

Síntomas gastrointestinales

80% de mejora

Naturlig energi

Variabilidad de la frecuencia cardíaca

18% de mejora

Anomalías de la Frecuencia Cardíaca Postural

45% de reducción

Estrés oxidativo

28% de reducción

Memoria

mejora del 32%

Lectura

mejora del 29%

Macrocirculación

mejora del 50%

Rendimiento Máximo

Microcirculación

mejora del 64%

Déficit de atención

11% de reducción

Palpitaciones

85% de reducción

Función del músculo cardíaco

29% de mejora

Presión arterial

10% de reducción

Resultados en poblaciones de estudio específicas. Los resultados individuales pueden variar.

Estudios dirigidos de forma independiente en colaboración con instituciones líderes

Desarrollamos nuestro trabajo en colaboración con prestigiosas instituciones de investigación que lideran y financian de manera independiente los ensayos clínicos en poblaciones clínicas diversas

Investigación sobre Nurosym de un vistazo

Avance pionero
Primer sistema no invasivo de neuromodulación vagal con marcado CE
Logro Significativo
Recomendado por más de 1.000 profesionales sanitarios titulados
Amplia colaboración
Colaboración con más de 100 socios de investigación de categoría mundial
Inversión significativa
Se han invertido $10M en investigación clínica con la tecnología patentada de Nurosym
Validación exhaustiva
Más de 60 publicaciones de estudios clínicos revisados por pares sobre Nurosym
Exploración robusta
Más de 100 ensayos clínicos en curso

Frequently asked questions

Nurosym is built on decades of scientific research and is recommended by 1000+ licensed healthcare professionals.

What is the difference between VNS, taVNS and AVNT™?

How is Nurosym different from a TENS device?

Where can I review the full publications?

Are the studies randomised and placebo-controlled?

How large are the clinical studies?

Who conducts the research, and is it independent?

Is the stimulation protocol standardised across studies?

Have any side effects been reported?

Why is further clinical research necessary?

Why does Nurosym cost more than a general electrical stimulation device?

Experimenta el Futuro de la Medicina Bioeléctrica.

Obtenga 70 € de descuento en el sistema VNS más estudiado

Participe en nuestra misión de impulsar la investigación en neuromodulación y obtenga 70 € de descuento en su dispositivo al completar el estudio.

* Toma menos de 2 minutos completarlo.

Obtenga 70 € de descuento

Fuentes

1. Zheng et al 2024 / Zheng, Z. S., Simonian, N., Wang, J., & Rosario, E. R. (2024). Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: a pilot study. Frontiers in neurology, 15, 1393371. https://doi.org/10.3389/fneur.2024.1393371


2. Verbanck et al 2021 / Verbanck, P., Clarinval, A. M., Burton, F., Corazza, F., Nagant, C., & Cheron, G. (2021). Transcutaneous auricular vagus nerve stimulation (tVNS) can reverse the manifestations of the Long-COVID syndrome: A pilot study. Frontiers in Neurology and Neuroscience Research, 2, Article 100011. https://quintet.no/wp-content/uploads/2023/11/transcutaneous-auricular-vagus-nerve[…]ifestations-of-the-long-covid-syndrome-a-pilot-study-100011.pdf


3. Dolcini et al 2025 / Dolcini, G., Favretti, M., Franculli, D., Buoncuore, G., Pellegrino, G., Di Carlo, M., Sarzi-Puttini, P., Conti, F., Iannuccielli, C., & Di Franco, M. (2025). Vagal nerve stimulation and fibromyalgia: an additional therapeutic option. Clinical and experimental rheumatology, 43(6), 1095–1104. https://doi.org/10.55563/clinexprheumatol/johqvo


4. Mbikyo et al 2024 / Mbikyo, M. B., Wang, A., Ma, Q., Miao, L., Cui, N., Yang, Y., Fu, H., Sun, Y., & Li, Z. (2024). Low-Level Tragus Stimulation Attenuates Blood Pressure in Young Individuals With Hypertension: Results From a Small–Scale Single–Blind Controlled Randomized Clinical Trial. Journal of the American Heart Association, 13(19), e032269. https://doi.org/10.1161/JAHA.123.032269


5. Thakkar et al 2023 / Thakkar, V. J., Richardson, Z. A., Dang, A., & Centanni, T. M. (2023). The effect of non-invasive vagus nerve stimulation on memory recall in reading: A pilot study. Behavioural brain research, 438, 114164. https://doi.org/10.1016/j.bbr.2022.114164


6. Dasari et al 2023 / University of Oklahoma Health Sciences Center / Dasari, T. W., Akhtar, K. H., Amil, F., Zhao, Y. D., Sohinki, D., Po, S. (2023). Effects of low level tragus stimulation on inflammation in acute decompensated heart failure. Journal of Cardiac Failure. 29(4): 660–661. https://doi.org/10.1016/j.cardfail.2022.10.278


7. Jackowska et al 2022 / Jackowska, M., Koenig, J., Vasendova, V., & Jandackova, V. K. (2022). A two-week course of transcutaneous vagal nerve stimulation improves global sleep: Findings from a randomised trial in community-dwelling adults. Autonomic neuroscience : basic & clinical, 240, 102972. https://doi.org/10.1016/j.autneu.2022.102972


8. Stavrakis et al 2024 / University of Oklahoma Health Sciences Center / Stavrakis, S., Chakraborty, P., Farhat, K., Whyte, S., Morris, L., Abideen Asad, Z. U., Karfonta, B., Anjum, J., Matlock, H. G., Cai, X., & Yu, X. (2024). Noninvasive Vagus Nerve Stimulation in Postural Tachycardia Syndrome: A Randomized Clinical Trial. JACC. Clinical electrophysiology, 10(2), 346–355. https://doi.org/10.1016/j.jacep.2023.10.015

Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com
Popup Title - Nurosym.com